ENTREZ ID;Symbol;updown;GENE NAME;log Fold Change;Averave Expression;P. value;Adjusted P. Value
51142;CHCHD2;up;coiled-coil-helix-coiled-coil-helix domain containing 2;-7.592197141;1.576911909;3.89E-08;4.62E-05
50805;IRX4;up;iroquois homeobox 4;-7.311519976;3.223559862;1.29E-07;6.03E-05
7620;ZNF69;up;zinc finger protein 69;-6.903030085;-0.865203914;1.53E-07;6.51E-05
91392;ZNF502;up;zinc finger protein 502;-6.700565417;-0.966709802;4.54E-07;8.80E-05
100131138;LINC01405;up;long intergenic non-protein coding RNA 1405;-6.405225784;-0.335755363;2.27E-07;7.31E-05
84527;ZNF559;up;zinc finger protein 559;-6.355935259;-1.136937834;2.90E-07;8.23E-05
11274;USP18;up;ubiquitin specific peptidase 18;-6.336239988;0.680862698;9.40E-08;5.66E-05
440556;LINC00982;up;long intergenic non-protein coding RNA 982;-5.910540395;1.873078526;4.69E-07;8.84E-05
100131827;ZNF717;up;zinc finger protein 717;-5.606630581;-0.217172694;2.05E-07;7.07E-05
389432;SAMD5;up;sterile alpha motif domain containing 5;-5.230269255;-1.698434186;4.98E-06;0.000347384
113146;AHNAK2;up;AHNAK nucleoprotein 2;-5.095059877;2.51661805;1.33E-07;6.03E-05
126068;ZNF441;up;zinc finger protein 441;-4.966130755;1.316341735;2.94E-05;0.000954343
63976;PRDM16;up;PR domain containing 16;-4.865992339;3.515366762;1.32E-07;6.03E-05
29797;POM121L8P;up;POM121 transmembrane nucleoporin-like 8 pseudogene;-4.639998575;2.069125325;5.09E-08;5.25E-05
101928200;MRGPRF-AS1;up;MRGPRF antisense RNA 1;-4.470747041;-1.545273614;6.84E-06;0.000411663
1812;DRD1;up;dopamine receptor D1;-4.425061915;1.542560116;1.79E-05;0.000727866
340990;OTOG;up;otogelin;-4.403375839;-2.10690355;1.73E-05;0.000716793
120892;LRRK2;up;leucine-rich repeat kinase 2;-4.317206274;0.183903039;2.20E-05;0.000806402
149837;LINC00654;up;long intergenic non-protein coding RNA 654;-4.28507109;0.287358954;1.99E-05;0.000763101
160777;CCDC60;up;coiled-coil domain containing 60;-4.168128766;-0.499712029;0.000166337;0.00283931
23493;HEY2;up;hes-related family bHLH transcription factor with YRPW motif 2;-4.152862583;2.707469148;9.31E-08;5.66E-05
4613;MYCN;up;v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog;-4.127427494;3.576011198;5.72E-08;5.28E-05
146429;SLC22A31;up;solute carrier family 22, member 31;-4.026147454;0.996124649;1.23E-06;0.000151116
2679;GGT3P;up;gamma-glutamyltransferase 3 pseudogene;-4.021863433;2.573869221;8.42E-08;5.66E-05
55026;TMEM255A;up;transmembrane protein 255A;-3.939151105;1.327119916;9.79E-05;0.001989428
7412;VCAM1;up;vascular cell adhesion molecule 1;-3.934469384;6.372696234;1.06E-08;4.62E-05
153571;C5orf38;up;chromosome 5 open reading frame 38;-3.898019954;1.018537048;6.29E-07;0.000104326
8538;BARX2;up;BARX homeobox 2;-3.83318853;-0.957665886;0.000359749;0.004882671
7472;WNT2;up;wingless-type MMTV integration site family member 2;-3.714968815;2.930134114;1.85E-05;0.000735059
25849;PARM1;up;prostate androgen-regulated mucin-like protein 1;-3.639851592;5.477565689;2.20E-08;4.62E-05
345557;PLCXD3;up;phosphatidylinositol-specific phospholipase C, X domain containing 3;-3.635504245;6.421699834;1.44E-07;6.30E-05
645367;GGT8P;up;gamma-glutamyltransferase 8 pseudogene;-3.55270658;1.57545242;6.92E-07;0.000107619
94121;SYTL4;up;synaptotagmin-like 4;-3.5121362;3.4596464;1.02E-07;5.66E-05
644943;RASSF10;up;Ras association (RalGDS/AF-6) domain family (N-terminal) member 10;-3.453850171;-0.037342274;7.45E-05;0.001659069
56911;MAP3K7CL;up;MAP3K7 C-terminal like;-3.415173243;0.852045232;2.52E-05;0.000877052
3910;LAMA4;up;laminin, alpha 4;-3.344762103;6.897458694;1.23E-05;0.000584482
147495;APCDD1;up;adenomatosis polyposis coli down-regulated 1;-3.343600914;3.465526567;1.49E-06;0.000165739
6331;SCN5A;up;sodium channel, voltage gated, type V alpha subunit;-3.301783691;3.080782446;1.71E-07;7.07E-05
153572;IRX2;up;iroquois homeobox 2;-3.288848086;4.012064664;1.94E-08;4.62E-05
2702;GJA5;up;gap junction protein, alpha 5, 40kDa;-3.219624507;-0.997868551;7.35E-05;0.001644376
116535;MRGPRF;up;MAS-related GPR, member F;-3.178222273;1.152596431;4.64E-06;0.000333409
79192;IRX1;up;iroquois homeobox 1;-3.170618005;0.815061089;4.68E-06;0.000333624
646074;POM121L10P;up;POM121 transmembrane nucleoporin-like 10, pseudogene;-3.009358323;1.074984073;3.64E-05;0.001087982
26220;DGCR5;up;DiGeorge syndrome critical region gene 5 (non-protein coding);-2.921694263;-0.828657425;0.000794451;0.008196659
6523;SLC5A1;up;solute carrier family 5 (sodium/glucose cotransporter), member 1;-2.921413752;-0.208861901;0.001829038;0.014411023
55971;BAIAP2L1;up;BAI1-associated protein 2-like 1;-2.863885778;4.136026361;1.57E-06;0.000169296
90627;STARD13;up;StAR-related lipid transfer (START) domain containing 13;-2.83397249;2.782635947;3.89E-07;8.61E-05
642633;FAM230B;up;family with sequence similarity 230, member B (non-protein coding);-2.770709393;-0.12014226;0.000151276;0.002690226
84894;LINGO1;up;leucine rich repeat and Ig domain containing 1;-2.718475253;4.586010687;6.08E-06;0.000394618
2274;FHL2;up;four and a half LIM domains 2;-2.688199262;6.692155056;4.15E-08;4.62E-05
28959;TMEM176B;up;transmembrane protein 176B;-2.666822425;2.950163319;7.38E-07;0.000109573
10396;ATP8A1;up;ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1;-2.650524286;4.881494479;7.07E-07;0.000108803
89796;NAV1;up;neuron navigator 1;-2.650064638;7.821605095;1.23E-09;1.78E-05
489;ATP2A3;up;ATPase, Ca++ transporting, ubiquitous;-2.622436278;2.228420049;1.46E-05;0.000649506
4916;NTRK3;up;neurotrophic tyrosine kinase, receptor, type 3;-2.588591361;-0.015567819;0.000416508;0.005386292
4633;MYL2;up;myosin, light chain 2, regulatory, cardiac, slow;-2.574432955;0.031120171;0.00014144;0.00255618
3739;KCNA4;up;potassium channel, voltage gated shaker related subfamily A, member 4;-2.54891556;2.906530127;2.47E-05;0.000871454
54756;IL17RD;up;interleukin 17 receptor D;-2.546887451;4.120318184;2.08E-06;0.000204532
57480;PLEKHG1;up;pleckstrin homology domain containing, family G (with RhoGef domain) member 1;-2.546490994;1.854184928;1.07E-05;0.000530704
112609;MRAP2;up;melanocortin 2 receptor accessory protein 2;-2.510359042;2.508273686;1.65E-05;0.00070361
2687;GGT5;up;gamma-glutamyltransferase 5;-2.43350714;0.479289282;8.43E-05;0.00178252
22986;SORCS3;up;sortilin-related VPS10 domain containing receptor 3;-2.428728338;4.626939526;5.94E-08;5.28E-05
101928656;LINC01099;up;long intergenic non-protein coding RNA 1099;-2.424390566;-0.869016539;0.000360224;0.004882671
219537;SMTNL1;up;smoothelin-like 1;-2.422020731;0.476499907;0.000903345;0.00894559
147841;SPC24;up;SPC24, NDC80 kinetochore complex component;-2.417253575;-0.262940066;0.000498558;0.006036979
23316;CUX2;up;cut-like homeobox 2;-2.405144006;0.916604195;0.000303334;0.004283911
4128;MAOA;up;monoamine oxidase A;-2.393466664;2.07778784;1.04E-05;0.000523636
54959;ODAM;up;odontogenic, ameloblast asssociated;-2.381469658;1.669054178;0.000676214;0.007417833
1740;DLG2;up;discs, large homolog 2 (Drosophila);-2.345082734;2.632141319;4.49E-06;0.000326242
375057;C1orf95;up;chromosome 1 open reading frame 95;-2.340395832;4.77524735;1.11E-07;5.96E-05
5521;PPP2R2B;up;protein phosphatase 2, regulatory subunit B, beta;-2.329401313;0.479670003;0.004801085;0.028612568
253044;LINGO1-AS1;up;LINGO1 antisense RNA 1;-2.325940377;0.212637805;0.001619282;0.013338339
6875;TAF4B;up;TAF4b RNA polymerase II, TATA box binding protein (TBP)-associated factor, 105kDa;-2.304242685;1.170226261;4.50E-05;0.001201195
284312;ZSCAN1;up;zinc finger and SCAN domain containing 1;-2.2889758;2.022330761;1.68E-05;0.00070703
55365;TMEM176A;up;transmembrane protein 176A;-2.26459863;2.305764562;9.43E-06;0.000497513
81610;FAM83D;up;family with sequence similarity 83, member D;-2.260949013;1.713486214;0.000576892;0.006667232
100874107;MTUS2-AS1;up;MTUS2 antisense RNA 1;-2.257619134;0.282601657;0.000177024;0.002952031
1040;CDS1;up;CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1;-2.257385606;1.624042006;2.24E-05;0.000815808
7691;ZNF132;up;zinc finger protein 132;-2.256262984;1.392240657;8.75E-05;0.001827462
10699;CORIN;up;corin, serine peptidase;-2.255520874;7.504530169;3.52E-08;4.62E-05
57699;CPNE5;up;copine V;-2.230243393;5.875257151;8.22E-07;0.000116506
27035;NOX1;up;NADPH oxidase 1;-2.228065802;0.274650527;0.0002117;0.003312502
79180;EFHD2;up;EF-hand domain family, member D2;-2.214527543;3.532199507;4.48E-07;8.80E-05
728978;UNC5B-AS1;up;UNC5B antisense RNA 1;-2.213816364;1.948532224;5.60E-06;0.000373247
960;CD44;up;CD44 molecule (Indian blood group);-2.204773812;1.466836281;0.002175547;0.016188198
60680;CELF5;up;CUGBP, Elav-like family member 5;-2.203581086;2.616311665;0.000154617;0.002717859
9787;DLGAP5;up;discs, large (Drosophila) homolog-associated protein 5;-2.186361971;2.667167556;4.42E-05;0.001190712
148534;TMEM56;up;transmembrane protein 56;-2.175079468;4.349715504;2.34E-06;0.000223674
332;BIRC5;up;baculoviral IAP repeat containing 5;-2.168621214;1.858477103;0.000435556;0.005538496
7049;TGFBR3;up;transforming growth factor, beta receptor III;-2.160846156;0.706304709;0.002935546;0.020346174
84530;SRRM4;up;serine/arginine repetitive matrix 4;-2.14414982;2.319618746;1.50E-05;0.000660905
9928;KIF14;up;kinesin family member 14;-2.141404806;2.726951981;2.66E-05;0.000898018
4288;MKI67;up;marker of proliferation Ki-67;-2.135996262;4.535633064;7.98E-05;0.001721989
55165;CEP55;up;centrosomal protein 55kDa;-2.121833975;1.434202877;0.00042847;0.005490774
100131244;ANKRD63;up;ankyrin repeat domain 63;-2.114906429;1.264042185;0.003173028;0.021507569
101928370;LOC101928370;up;uncharacterized LOC101928370;-2.111915469;-0.059905442;0.001394037;0.012090572
863;CBFA2T3;up;core-binding factor, runt domain, alpha subunit 2| translocated to, 3;-2.111896807;2.254193867;2.19E-05;0.000806402
NA;LOC101927221;up;NA;-2.105775216;-0.210218979;0.000454014;0.005686993
116969;ART5;up;ADP-ribosyltransferase 5;-2.095268117;2.602556654;3.83E-05;0.001114336
100130476;LOC100130476;up;uncharacterized LOC100130476;-2.088655394;-0.211234606;0.001662878;0.013590667
10821;OR7E12P;up;olfactory receptor, family 7, subfamily E, member 12 pseudogene;-2.088653716;1.52935019;3.51E-05;0.001073739
80757;TMEM121;up;transmembrane protein 121;-2.072532033;0.885618522;0.000111747;0.002183293
81029;WNT5B;up;wingless-type MMTV integration site family, member 5B;-2.034012347;4.949534045;1.82E-07;7.07E-05
79875;THSD4;up;thrombospondin, type I, domain containing 4;-2.027713325;3.383268646;1.31E-05;0.000601611
254122;SNX32;up;sorting nexin 32;-2.027354469;2.113819276;3.59E-05;0.001080024
650368;TSSC2;up;tumor suppressing subtransferable candidate 2 pseudogene;-2.027121267;2.902310746;1.42E-05;0.00063753
9034;CCRL2;up;chemokine (C-C motif) receptor-like 2;-2.023100788;1.249779634;0.000591087;0.006766378
6457;SH3GL3;up;SH3-domain GRB2-like 3;-2.0175576;3.381265427;1.06E-06;0.000137383
376132;LRRC10;up;leucine rich repeat containing 10;-2.01592469;5.416487152;6.64E-06;0.000407036
80119;PIF1;up;PIF1 5'-to-3' DNA helicase;-2.008109773;2.361387023;3.45E-05;0.001061771
55635;DEPDC1;up;DEP domain containing 1;-1.992741126;2.886195128;9.09E-06;0.000486276
114822;RHPN1;up;rhophilin, Rho GTPase binding protein 1;-1.976009124;2.495354461;0.000329621;0.004547388
9768;KIAA0101;up;KIAA0101;-1.975765548;0.951325091;0.001196334;0.010864699
10112;KIF20A;up;kinesin family member 20A;-1.973762813;3.389015677;1.94E-05;0.000748727
259266;ASPM;up;abnormal spindle microtubule assembly;-1.969065209;3.822589535;3.76E-05;0.001106189
91768;CABLES1;up;Cdk5 and Abl enzyme substrate 1;-1.968540917;2.212455859;5.10E-05;0.001305023
10024;TROAP;up;trophinin associated protein;-1.964534167;2.723277979;0.000227651;0.003473824
9212;AURKB;up;aurora kinase B;-1.953776711;1.689598773;0.000115769;0.002234692
4751;NEK2;up;NIMA-related kinase 2;-1.946659098;1.510494057;7.94E-05;0.001718722
138046;RALYL;up;RALY RNA binding protein-like;-1.941802485;0.626028919;0.002745115;0.019398278
23566;LPAR3;up;lysophosphatidic acid receptor 3;-1.940510933;1.538723117;0.000277934;0.004028266
146909;KIF18B;up;kinesin family member 18B;-1.936406856;2.357148685;0.000176835;0.002952031
100507032;TMCC1-AS1;up;TMCC1 antisense RNA 1 (head to head);-1.933035792;2.717474064;2.62E-05;0.00088908
9232;PTTG1;up;pituitary tumor-transforming 1;-1.930065194;3.320847778;4.94E-05;0.001281234
65078;RTN4R;up;reticulon 4 receptor;-1.928927596;-0.448477606;0.001441335;0.012359917
28965;SLC27A6;up;solute carrier family 27 (fatty acid transporter), member 6;-1.928169642;5.145501615;7.92E-05;0.001716948
8817;FGF18;up;fibroblast growth factor 18;-1.927401131;4.179949546;3.96E-07;8.61E-05
283431;GAS2L3;up;growth arrest-specific 2 like 3;-1.919994194;1.192078071;0.00037346;0.00500064
4878;NPPA;up;natriuretic peptide A;-1.919585687;5.651981729;0.001980013;0.01517076
5625;PRODH;up;proline dehydrogenase (oxidase) 1;-1.900285511;3.296157827;4.37E-05;0.001188112
10403;NDC80;up;NDC80 kinetochore complex component;-1.898904716;1.81155263;9.17E-05;0.001890367
6533;SLC6A6;up;solute carrier family 6 (neurotransmitter transporter), member 6;-1.889268114;5.104956794;3.65E-07;8.61E-05
387882;C12orf75;up;chromosome 12 open reading frame 75;-1.871852846;4.000364708;3.67E-06;0.000290249
84057;MND1;up;meiotic nuclear divisions 1;-1.868070694;0.14354419;0.00091271;0.009019792
157313;CDCA2;up;cell division cycle associated 2;-1.862892898;1.985196279;0.000350609;0.00480484
55872;PBK;up;PDZ binding kinase;-1.85742777;1.504372429;0.000373449;0.00500064
11113;CIT;up;citron rho-interacting serine/threonine kinase;-1.848399817;2.413422144;0.00018127;0.002991787
29091;STXBP6;up;syntaxin binding protein 6 (amisyn);-1.846138922;2.776713805;1.21E-05;0.000578048
4166;CHST6;up;carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6;-1.845052149;2.030701043;4.23E-05;0.00116606
80125;CCDC33;up;coiled-coil domain containing 33;-1.839608014;0.413564191;0.000638159;0.007119213
55771;PRR11;up;proline rich 11;-1.838121096;2.967190096;7.21E-06;0.000425636
29940;DSE;up;dermatan sulfate epimerase;-1.836799169;4.52598265;1.51E-06;0.000166555
9633;MTL5;up;metallothionein-like 5, testis-specific (tesmin);-1.831457072;2.115164842;0.000244364;0.003672577
7222;TRPC3;up;transient receptor potential cation channel, subfamily C, member 3;-1.831251223;4.506099771;4.92E-07;8.84E-05
8842;PROM1;up;prominin 1;-1.826637346;2.228516661;0.000427592;0.005490774
85452;CFAP74;up;cilia and flagella associated protein 74;-1.82251301;0.764798799;0.00035597;0.004850727
56915;EXOSC5;up;exosome component 5;-1.82080634;2.873911263;7.11E-06;0.00042117
7153;TOP2A;up;topoisomerase (DNA) II alpha;-1.804537407;5.086454992;4.60E-05;0.001221228
93556;EGFEM1P;up;EGF-like and EMI domain containing 1, pseudogene;-1.801522353;2.23824339;2.53E-05;0.000877335
4306;NR3C2;up;nuclear receptor subfamily 3, group C, member 2;-1.80051288;-0.096446298;0.000782294;0.008113007
3161;HMMR;up;hyaluronan-mediated motility receptor (RHAMM);-1.797155555;2.421087765;0.000133817;0.002457713
9892;SNAP91;up;synaptosomal-associated protein, 91kDa;-1.793633924;3.662763085;0.000465783;0.005785473
54478;FAM64A;up;family with sequence similarity 64, member A;-1.791901268;1.146300617;0.000218144;0.003384038
991;CDC20;up;cell division cycle 20;-1.785270665;2.868735369;5.04E-05;0.00129685
54082;TSPEAR-AS1;up;TSPEAR antisense RNA 1;-1.784574029;5.189431309;4.92E-07;8.84E-05
11004;KIF2C;up;kinesin family member 2C;-1.783658356;2.899941893;4.31E-05;0.001182193
10631;POSTN;up;periostin, osteoblast specific factor;-1.781005459;3.267148548;6.86E-06;0.000411663
3958;LGALS3;up;lectin, galactoside-binding, soluble, 3;-1.776537388;2.595326798;3.85E-05;0.001115138
1058;CENPA;up;centromere protein A;-1.773250887;0.306369996;0.001165989;0.010688649
55997;CFC1;up;cripto, FRL-1, cryptic family 1;-1.763461227;1.914736204;7.14E-05;0.001620976
57565;KLHL14;up;kelch-like family member 14;-1.763159799;6.185446609;6.68E-07;0.000106172
1396;CRIP1;up;cysteine-rich protein 1 (intestinal);-1.757525554;5.423329178;2.16E-07;7.25E-05
3386;ICAM4;up;intercellular adhesion molecule 4 (Landsteiner-Wiener blood group);-1.753856678;1.409389055;0.000751039;0.007946956
3908;LAMA2;up;laminin, alpha 2;-1.74444762;7.087935805;5.73E-06;0.000379961
23397;NCAPH;up;non-SMC condensin I complex, subunit H;-1.742738392;1.440206794;0.002288756;0.016797381
7272;TTK;up;TTK protein kinase;-1.742158275;2.037563774;0.000195518;0.003137407
9133;CCNB2;up;cyclin B2;-1.736773871;2.748827085;6.87E-05;0.001582179
10974;ADIRF;up;adipogenesis regulatory factor;-1.732822987;1.294797259;0.001670505;0.013629886
154;ADRB2;up;adrenoceptor beta 2, surface;-1.72601001;2.83588636;2.72E-05;0.000909256
100131539;ZNF705E;up;zinc finger protein 705E;-1.713357076;0.290509145;0.000755754;0.007959051
60676;PAPPA2;up;pappalysin 2;-1.712412386;1.911189558;0.000242163;0.003650873
53405;CLIC5;up;chloride intracellular channel 5;-1.70634961;4.246800333;3.96E-06;0.000300497
7547;ZIC3;up;Zic family member 3;-1.706102569;0.905023413;0.001196127;0.010864699
79746;ECHDC3;up;enoyl CoA hydratase domain containing 3;-1.699738231;3.724868342;3.95E-06;0.000300497
5791;PTPRE;up;protein tyrosine phosphatase, receptor type, E;-1.698436312;2.8580945;0.000328619;0.004542226
91862;MARVELD3;up;MARVEL domain containing 3;-1.697566576;0.869395256;0.002730383;0.019303607
8214;DGCR6;up;DiGeorge syndrome critical region gene 6;-1.697201838;5.329150863;8.39E-06;0.000464606
64105;CENPK;up;centromere protein K;-1.696388819;1.1613269;0.000206795;0.003285537
128239;IQGAP3;up;IQ motif containing GTPase activating protein 3;-1.696163113;3.304368131;0.000116912;0.002244768
84630;TTBK1;up;tau tubulin kinase 1;-1.689087512;0.88921592;0.001064284;0.009998318
1063;CENPF;up;centromere protein F, 350/400kDa;-1.684017547;4.748979727;2.78E-05;0.000919972
214;ALCAM;up;activated leukocyte cell adhesion molecule;-1.673526703;5.486598953;2.84E-05;0.000932644
701;BUB1B;up;BUB1 mitotic checkpoint serine/threonine kinase B;-1.671671594;3.378931685;0.000148913;0.002664588
163782;KANK4;up;KN motif and ankyrin repeat domains 4;-1.666741185;1.00022706;0.003284321;0.022014239
22983;MAST1;up;microtubule associated serine/threonine kinase 1;-1.664271585;0.798607609;0.001441096;0.012359917
284;ANGPT1;up;angiopoietin 1;-1.663787062;6.561363917;0.000108746;0.002142028
55355;HJURP;up;Holliday junction recognition protein;-1.656570097;2.226939123;0.000321418;0.004470918
100507661;LOC100507661;up;uncharacterized LOC100507661;-1.654715439;1.273599365;0.000773334;0.008043785
55010;PARPBP;up;PARP1 binding protein;-1.652623611;0.738374933;0.004803094;0.028612747
83540;NUF2;up;NUF2, NDC80 kinetochore complex component;-1.650285314;2.032497152;0.000375125;0.005012527
440503;PLIN5;up;perilipin 5;-1.643847248;2.031842943;8.11E-05;0.001732441
1910;EDNRB;up;endothelin receptor type B;-1.640938792;2.531466274;4.47E-05;0.001197491
55247;NEIL3;up;nei-like DNA glycosylase 3;-1.638259888;-0.429835543;0.009151225;0.044911204
152;ADRA2C;up;adrenoceptor alpha 2C;-1.637633849;0.532032371;0.000969221;0.009360719
100861541;DOCK9-AS2;up;DOCK9 antisense RNA 2 (head to head);-1.635841728;0.775982264;0.000906961;0.008975247
23281;MTUS2;up;microtubule associated tumor suppressor candidate 2;-1.635826603;6.665719692;2.84E-06;0.000250778
5336;PLCG2;up;phospholipase C, gamma 2 (phosphatidylinositol-specific);-1.630365984;4.081112478;2.51E-06;0.000229711
64798;DEPTOR;up;DEP domain containing MTOR-interacting protein;-1.624713767;0.587503303;0.001286674;0.011454882
3767;KCNJ11;up;potassium channel, inwardly rectifying subfamily J, member 11;-1.621563713;4.045011041;8.18E-06;0.000460058
1062;CENPE;up;centromere protein E, 312kDa;-1.62144105;3.629323081;7.99E-05;0.001721989
10630;PDPN;up;podoplanin;-1.621072577;4.612776349;4.23E-05;0.00116606
89;ACTN3;up;actinin, alpha 3 (gene/pseudogene);-1.620650399;6.859761263;0.005677427;0.032342098
399972;ST3GAL4-AS1;up;ST3GAL4 antisense RNA 1 (head to head);-1.61734256;1.419512671;0.000477224;0.005897178
6653;SORL1;up;sortilin-related receptor, L(DLR class) A repeats containing;-1.615411203;4.215998049;1.66E-05;0.00070361
79628;SH3TC2;up;SH3 domain and tetratricopeptide repeats 2;-1.605339265;2.084136472;0.000479804;0.005908799
118461;C10orf71;up;chromosome 10 open reading frame 71;-1.604393797;3.899826052;3.15E-06;0.000266512
57509;MTUS1;up;microtubule associated tumor suppressor 1;-1.600419299;4.702892855;9.49E-06;0.000498774
8654;PDE5A;up;phosphodiesterase 5A, cGMP-specific;-1.597230454;3.325060979;5.04E-05;0.00129685
100885775;BANCR;up;BRAF-activated non-protein coding RNA;-1.594053681;0.731491;0.004752564;0.02841711
8863;PER3;up;period circadian clock 3;-1.593041548;4.356300656;0.000159847;0.002771057
23089;PEG10;up;paternally expressed 10;-1.590356222;6.440419754;1.78E-06;0.000181228
9980;DOPEY2;up;dopey family member 2;-1.587420645;3.361156897;1.77E-05;0.000725498
995;CDC25C;up;cell division cycle 25C;-1.585499035;0.94381139;0.000923584;0.009089981
30812;SOX8;up;SRY (sex determining region Y)-box 8;-1.579954103;2.829129863;5.38E-05;0.001343691
158696;LINC00889;up;long intergenic non-protein coding RNA 889;-1.577737274;1.640578611;0.000488181;0.005966284
103689846;ADAMTS19-AS1;up;ADAMTS19 antisense RNA 1;-1.575802474;0.824989391;0.000768951;0.008022686
90423;ATP6V1E2;up;ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2;-1.574546983;0.605168633;0.000695255;0.007523945
10886;NPFFR2;up;neuropeptide FF receptor 2;-1.5740508;1.64143111;0.000208954;0.003298102
51512;GTSE1;up;G-2 and S-phase expressed 1;-1.57267613;2.286134128;0.001677763;0.013662332
642924;LINC00535;up;long intergenic non-protein coding RNA 535;-1.570576444;-0.102852742;0.002040905;0.015485467
890;CCNA2;up;cyclin A2;-1.567143864;3.448229077;6.51E-05;0.001525348
220992;ZNF485;up;zinc finger protein 485;-1.558965558;1.072513563;0.00158268;0.013135347
10076;PTPRU;up;protein tyrosine phosphatase, receptor type, U;-1.549203466;4.622159022;4.79E-06;0.00033938
114043;TSPEAR-AS2;up;TSPEAR antisense RNA 2;-1.544715961;4.054331581;6.30E-06;0.000397857
2894;GRID1;up;glutamate receptor, ionotropic, delta 1;-1.544466095;1.400421389;0.000382807;0.005068337
753;LDLRAD4;up;low density lipoprotein receptor class A domain containing 4;-1.540528896;1.743761673;0.000159304;0.00276624
55789;DEPDC1B;up;DEP domain containing 1B;-1.535836316;0.937864769;0.000805983;0.00827621
81620;CDT1;up;chromatin licensing and DNA replication factor 1;-1.531277389;1.677509051;0.000456751;0.005702678
221150;SKA3;up;spindle and kinetochore associated complex subunit 3;-1.531066946;0.628516398;0.003909145;0.024821442
983;CDK1;up;cyclin-dependent kinase 1;-1.529555919;3.415041233;2.60E-05;0.000883717
5454;POU3F2;up;POU class 3 homeobox 2;-1.527717263;0.426474706;0.003762412;0.024165682
64151;NCAPG;up;non-SMC condensin I complex, subunit G;-1.526967232;2.62945947;0.000478419;0.005906905
205147;AMER3;up;APC membrane recruitment protein 3;-1.524665081;-0.31145908;0.005115062;0.030001448
4703;NEB;up;nebulin;-1.52199419;3.519079285;4.50E-05;0.001201195
171019;ADAMTS19;up;ADAM metallopeptidase with thrombospondin type 1 motif, 19;-1.520755651;5.618023186;8.21E-06;0.000460172
23555;TSPAN15;up;tetraspanin 15;-1.520695748;5.521849384;4.56E-07;8.80E-05
57608;KIAA1462;up;KIAA1462;-1.520235308;5.383591576;5.63E-07;9.78E-05
101927726;BEAN1-AS1;up;BEAN1 antisense RNA 1;-1.502431155;0.157005223;0.002197545;0.016301748
6692;SPINT1;up;serine peptidase inhibitor, Kunitz type 1;-1.500786319;1.645409203;0.000935113;0.009166005
90134;KCNH7;up;potassium channel, voltage gated eag related subfamily H, member 7;-1.499407058;6.398401265;5.77E-05;0.001405556
728229;TMEM191B;up;transmembrane protein 191B;-1.495823249;0.228566382;0.001699991;0.013769455
220965;FAM13C;up;family with sequence similarity 13, member C;-1.494252293;2.807896073;0.000174536;0.002920657
26047;CNTNAP2;up;contactin associated protein-like 2;-1.492186961;3.878224401;0.000208917;0.003298102
11065;UBE2C;up;ubiquitin-conjugating enzyme E2C;-1.486965558;2.638356818;6.30E-05;0.001496825
5023;P2RX1;up;purinergic receptor P2X, ligand gated ion channel, 1;-1.486488698;1.086591882;0.000668675;0.007351871
9421;HAND1;up;heart and neural crest derivatives expressed 1;-1.481821097;3.442259829;0.000146927;0.002635567
2013;EMP2;up;epithelial membrane protein 2;-1.480774087;6.952997257;5.54E-05;0.001367703
5309;PITX3;up;paired-like homeodomain 3;-1.476461843;-0.578443608;0.010617091;0.049838279
55723;ASF1B;up;anti-silencing function 1B histone chaperone;-1.468962747;1.169080191;0.002286584;0.016789962
990;CDC6;up;cell division cycle 6;-1.468072186;1.355488791;0.002321449;0.016968404
151473;SLC16A14;up;solute carrier family 16, member 14;-1.461554699;3.877923635;2.11E-05;0.000792092
144577;C12orf66;up;chromosome 12 open reading frame 66;-1.459210446;2.059395615;0.000162078;0.002792988
5077;PAX3;up;paired box 3;-1.455296113;2.865771886;2.55E-05;0.000880689
100505549;LOC100505549;up;uncharacterized LOC100505549;-1.454083968;0.304833448;0.0014511;0.012406863
2152;F3;up;coagulation factor III (thromboplastin, tissue factor);-1.451990035;1.547001977;0.000685946;0.007479189
81543;LRRC3;up;leucine rich repeat containing 3;-1.450289018;2.7057015;0.000492503;0.006003688
135138;PACRG;up;PARK2 co-regulated;-1.44838967;0.884824287;0.001236026;0.011125375
64859;NABP1;up;nucleic acid binding protein 1;-1.445307932;1.996500264;0.000395314;0.005167677
222663;SCUBE3;up;signal peptide, CUB domain, EGF-like 3;-1.444748717;6.986198974;8.38E-06;0.000464606
5865;RAB3B;up;RAB3B, member RAS oncogene family;-1.44293882;3.840967382;8.66E-05;0.001817275
92815;HIST3H2A;up;histone cluster 3, H2a;-1.442287046;1.609582517;0.000352685;0.004820703
140738;TMEM37;up;transmembrane protein 37;-1.439979401;0.438063526;0.002523474;0.018142412
150763;GPAT2;up;glycerol-3-phosphate acyltransferase 2, mitochondrial;-1.439874896;2.136110086;0.00012845;0.002399402
84254;CAMKK1;up;calcium/calmodulin-dependent protein kinase kinase 1, alpha;-1.431810575;3.507719911;0.000208199;0.003297781
57537;SORCS2;up;sortilin-related VPS10 domain containing receptor 2;-1.430600429;3.163317452;0.000101023;0.002039928
147837;ZNF563;up;zinc finger protein 563;-1.427261525;0.490829796;0.005002828;0.029462685
24137;KIF4A;up;kinesin family member 4A;-1.425735241;2.494296473;0.000522695;0.006240396
2177;FANCD2;up;Fanconi anemia, complementation group D2;-1.422807103;3.693415921;1.91E-05;0.000740956
10683;DLL3;up;delta-like 3 (Drosophila);-1.421218372;1.515898656;0.001283805;0.011436389
10125;RASGRP1;up;RAS guanyl releasing protein 1 (calcium and DAG-regulated);-1.412731347;2.882709869;0.001190919;0.010835937
221692;PHACTR1;up;phosphatase and actin regulator 1;-1.412154871;2.927397735;0.000121433;0.002316101
100874362;HOXB-AS1;up;HOXB cluster antisense RNA 1;-1.411791557;3.226138111;0.0005431;0.006409906
5330;PLCB2;up;phospholipase C, beta 2;-1.411530637;4.677313073;4.41E-05;0.001190055
414149;ACBD7;up;acyl-CoA binding domain containing 7;-1.404052714;1.126307418;0.001998221;0.015262321
400084;LINC00939;up;long intergenic non-protein coding RNA 939;-1.4034434;0.267763684;0.003199899;0.021638978
18;ABAT;up;4-aminobutyrate aminotransferase;-1.396132335;6.554555222;0.000511173;0.006158778
26577;PCOLCE2;up;procollagen C-endopeptidase enhancer 2;-1.392430387;1.237188689;0.001105341;0.010257395
2258;FGF13;up;fibroblast growth factor 13;-1.392358648;5.824228159;5.00E-06;0.000347384
7023;TFAP4;up;transcription factor AP-4 (activating enhancer binding protein 4);-1.391316836;2.977195652;9.80E-05;0.001989428
225689;MAPK15;up;mitogen-activated protein kinase 15;-1.38118367;2.513213431;0.000303412;0.004283911
1259;CNGA1;up;cyclic nucleotide gated channel alpha 1;-1.381038294;0.985028847;0.001998311;0.015262321
729522;AACSP1;up;acetoacetyl-CoA synthetase pseudogene 1;-1.380823424;3.995439243;0.000716417;0.007693461
5355;PLP2;up;proteolipid protein 2 (colonic epithelium-enriched);-1.378054386;3.91609798;7.91E-05;0.001716948
149461;CLDN19;up;claudin 19;-1.378039321;1.97029662;0.002050868;0.015524323
55388;MCM10;up;minichromosome maintenance 10 replication initiation factor;-1.376414376;0.871587835;0.00547813;0.031580065
158326;FREM1;up;FRAS1 related extracellular matrix 1;-1.37494223;6.138427112;2.46E-05;0.00087104
84073;MYCBPAP;up;MYCBP associated protein;-1.373980844;1.748678216;0.004610923;0.027845863
150468;CKAP2L;up;cytoskeleton associated protein 2-like;-1.371640743;1.582118721;0.000764526;0.00800979
3212;HOXB2;up;homeobox B2;-1.368365573;4.134603175;2.50E-05;0.000876269
55143;CDCA8;up;cell division cycle associated 8;-1.364279401;2.202628196;0.00117426;0.010731635
64979;MRPL36;up;mitochondrial ribosomal protein L36;-1.361221863;3.871895213;2.87E-05;0.000937231
128434;VSTM2L;up;V-set and transmembrane domain containing 2 like;-1.35936141;5.994971988;0.000134942;0.00246338
3718;JAK3;up;Janus kinase 3;-1.356299879;2.422737259;0.000884008;0.008819921
151242;PPP1R1C;up;protein phosphatase 1, regulatory (inhibitor) subunit 1C;-1.354342461;0.928495987;0.001485459;0.012597502
29774;POM121L9P;up;POM121 transmembrane nucleoporin-like 9, pseudogene;-1.352429271;1.079143337;0.000872795;0.008750945
79570;NKAIN1;up;Na+/K+ transporting ATPase interacting 1;-1.350687352;1.541026024;0.000667019;0.007339241
148418;SAMD13;up;sterile alpha motif domain containing 13;-1.345816021;1.166717113;0.000740823;0.007864042
83461;CDCA3;up;cell division cycle associated 3;-1.338790361;1.763288072;0.001395604;0.012096906
4085;MAD2L1;up;MAD2 mitotic arrest deficient-like 1 (yeast);-1.335563787;2.837284695;0.000162807;0.002797977
100506394;GAS6-AS2;up;GAS6 antisense RNA 2 (head to head);-1.32915398;0.111423969;0.003815628;0.024367232
101927862;CTB-178M22.2;up;uncharacterized LOC101927862;-1.325622525;-0.037968406;0.006323799;0.034817015
100128682;LINC01531;up;long intergenic non-protein coding RNA 1531;-1.325265548;0.890869136;0.001686341;0.013687326
NA;LINC01573;up;NA;-1.324100764;2.45452248;0.000298945;0.004245729
3741;KCNA5;up;potassium channel, voltage gated shaker related subfamily A, member 5;-1.321063095;4.977616018;2.66E-05;0.000898018
57576;KIF17;up;kinesin family member 17;-1.320897726;0.953667992;0.004277101;0.026452032
10591;DNPH1;up;2'-deoxynucleoside 5'-phosphate N-hydrolase 1;-1.320835083;3.905692581;2.55E-05;0.000880689
134147;CMBL;up;carboxymethylenebutenolidase homolog (Pseudomonas);-1.320250253;3.726336849;4.56E-05;0.001210706
29941;PKN3;up;protein kinase N3;-1.318698445;3.635402466;0.00011845;0.002265274
646019;CBY3;up;chibby homolog 3 (Drosophila);-1.317315053;-0.173396453;0.004135943;0.02583044
29127;RACGAP1;up;Rac GTPase activating protein 1;-1.317166865;4.082718282;5.08E-05;0.001301477
10636;RGS14;up;regulator of G-protein signaling 14;-1.316385503;3.010419122;0.001361573;0.011916236
57817;HAMP;up;hepcidin antimicrobial peptide;-1.312437064;0.963889729;0.008478595;0.042504692
727758;ROCK1P1;up;Rho-associated, coiled-coil containing protein kinase 1 pseudogene 1;-1.31169902;0.563833772;0.004239847;0.026313463
9156;EXO1;up;exonuclease 1;-1.310215069;0.918862019;0.006937791;0.036999847
8501;SLC43A1;up;solute carrier family 43 (amino acid system L transporter), member 1;-1.309246378;2.964317845;0.000128356;0.002399402
4605;MYBL2;up;v-myb avian myeloblastosis viral oncogene homolog-like 2;-1.308184539;2.667234873;0.002435414;0.017596809
91133;L3MBTL4;up;l(3)mbt-like 4 (Drosophila);-1.299742502;3.491881935;2.58E-05;0.000882925
83990;BRIP1;up;BRCA1 interacting protein C-terminal helicase 1;-1.298081094;2.203755439;0.00239557;0.017383291
85461;TANC1;up;tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1;-1.296841024;6.381694858;2.64E-06;0.000238784
5774;PTPN3;up;protein tyrosine phosphatase, non-receptor type 3;-1.295758274;1.211280027;0.001407355;0.012162309
23328;SASH1;up;SAM and SH3 domain containing 1;-1.293956464;4.860614329;4.15E-06;0.000309642
118980;SFXN2;up;sideroflexin 2;-1.290997773;3.144241017;0.000291814;0.004169442
80309;SPHKAP;up;SPHK1 interactor, AKAP domain containing;-1.287362992;5.747202458;5.74E-05;0.00139848
9262;STK17B;up;serine/threonine kinase 17b;-1.280370526;1.634417768;0.002546988;0.018247942
440952;EIF1B-AS1;up;EIF1B antisense RNA 1;-1.277757931;0.34884469;0.004222656;0.026247273
23171;GPD1L;up;glycerol-3-phosphate dehydrogenase 1-like;-1.27692903;3.63781077;0.00102266;0.009720986
115207;KCTD12;up;potassium channel tetramerization domain containing 12;-1.27337567;8.20757167;1.82E-05;0.000731562
348487;FAM131C;up;family with sequence similarity 131, member C;-1.272956281;1.482790918;0.001075947;0.010072683
2869;GRK5;up;G protein-coupled receptor kinase 5;-1.272635176;6.050002561;4.74E-05;0.001247617
113130;CDCA5;up;cell division cycle associated 5;-1.269151639;1.856339593;0.002107175;0.015809825
100128640;ACVR2B-AS1;up;ACVR2B antisense RNA 1;-1.268480987;1.040256176;0.001620011;0.013338339
2887;GRB10;up;growth factor receptor-bound protein 10;-1.264378097;4.466753373;4.01E-05;0.001133678
81615;TMEM163;up;transmembrane protein 163;-1.263666542;5.439438509;9.59E-06;0.00050031
100498859;LINC00881;up;long intergenic non-protein coding RNA 881;-1.263290107;3.002852216;7.84E-05;0.001713776
126382;NR2C2AP;up;nuclear receptor 2C2-associated protein;-1.262862614;1.67520326;0.002593378;0.018497809
84867;PTPN5;up;protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched);-1.259138271;1.738003272;0.000751841;0.007946956
4145;MATK;up;megakaryocyte-associated tyrosine kinase;-1.244391889;0.673148813;0.009481481;0.04597526
11025;LILRB3;up;leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3;-1.241482185;0.668567088;0.004045416;0.025410117
9718;ECE2;up;endothelin converting enzyme 2;-1.240106967;0.761844102;0.003412807;0.022634111
2175;FANCA;up;Fanconi anemia, complementation group A;-1.23919592;2.786746371;0.001745675;0.01401974
2863;GPR39;up;G protein-coupled receptor 39;-1.238318367;1.507544575;0.001947981;0.015046547
54976;C20orf27;up;chromosome 20 open reading frame 27;-1.237983422;3.004557223;0.000186246;0.003045704
10370;CITED2;up;Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2;-1.236443153;7.20133947;8.56E-06;0.000470784
2305;FOXM1;up;forkhead box M1;-1.236346453;3.402488966;0.000578437;0.006679748
83903;GSG2;up;germ cell associated 2 (haspin);-1.235384947;0.5836533;0.005620571;0.032125837
341;APOC1;up;apolipoprotein C-I;-1.23441564;1.070768687;0.004714022;0.02830371
56935;SMCO4;up;single-pass membrane protein with coiled-coil domains 4;-1.234363512;4.661182495;1.09E-05;0.000534392
348926;FAM86EP;up;family with sequence similarity 86, member A pseudogene;-1.232896766;1.670930844;0.002065636;0.015611586
10721;POLQ;up;polymerase (DNA directed), theta;-1.230827761;2.461848106;0.000656795;0.007252427
9945;GFPT2;up;glutamine-fructose-6-phosphate transaminase 2;-1.229409729;4.755431588;1.57E-05;0.000681553
51725;FBXO40;up;F-box protein 40;-1.228434774;5.629568194;2.58E-05;0.000882925
116447;TOP1MT;up;topoisomerase (DNA) I, mitochondrial;-1.226981302;1.35510477;0.001787967;0.014221289
9055;PRC1;up;protein regulator of cytokinesis 1;-1.225180082;4.064833869;6.90E-05;0.001585026
102724312;LOC102724312;up;uncharacterized LOC102724312;-1.223695849;1.358821405;0.009485697;0.04597526
54511;HMGCLL1;up;3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1;-1.221630199;3.696175849;8.10E-05;0.001732417
2201;FBN2;up;fibrillin 2;-1.220512292;10.86173856;6.26E-05;0.001492169
2308;FOXO1;up;forkhead box O1;-1.220160126;3.274781033;0.001141446;0.010504793
51348;KLRF1;up;killer cell lectin-like receptor subfamily F, member 1;-1.218164141;0.537952196;0.003468292;0.022897065
6191;RPS4X;up;ribosomal protein S4, X-linked;-1.217209342;9.640410582;6.92E-07;0.000107619
29944;PNMA3;up;paraneoplastic Ma antigen 3;-1.216587734;4.307224626;3.82E-05;0.001113863
442132;LOC442132;up;golgin A6 family-like 1 pseudogene;-1.21505233;-0.01166353;0.007574307;0.039278811
56479;KCNQ5;up;potassium channel, voltage gated KQT-like subfamily Q, member 5;-1.21342957;6.240736518;0.000357456;0.004861804
7128;TNFAIP3;up;tumor necrosis factor, alpha-induced protein 3;-1.209599505;3.231519604;0.00010622;0.002109521
80000;GREB1L;up;growth regulation by estrogen in breast cancer-like;-1.208338806;3.425641788;0.000197739;0.003162518
339005;WHAMMP3;up;WAS protein homolog associated with actin, golgi membranes and microtubules pseudogene 3;-1.206566048;2.731651791;0.000384879;0.005084592
9241;NOG;up;noggin;-1.205529009;3.750851111;0.00061091;0.00688965
9246;UBE2L6;up;ubiquitin-conjugating enzyme E2L 6;-1.20026035;5.041459286;1.14E-05;0.00055475
10446;LRRN2;up;leucine rich repeat neuronal 2;-1.199961516;3.431542442;0.000138997;0.002518323
162461;TMEM92;up;transmembrane protein 92;-1.199048504;2.312216493;0.009885246;0.047450494
9781;RNF144A;up;ring finger protein 144A;-1.196085043;5.323298321;5.98E-06;0.000391384
51203;NUSAP1;up;nucleolar and spindle associated protein 1;-1.194221548;3.689718723;0.000429722;0.005493302
221178;SPATA13;up;spermatogenesis associated 13;-1.193899877;4.840649141;1.30E-05;0.000600287
79733;E2F8;up;E2F transcription factor 8;-1.193863167;3.945511098;2.77E-05;0.000919721
1188;CLCNKB;up;chloride channel, voltage-sensitive Kb;-1.191824758;4.523747395;0.000694388;0.007520198
57821;CCDC181;up;coiled-coil domain containing 181;-1.191365495;2.618036882;0.000272869;0.003964961
255031;LINC00957;up;long intergenic non-protein coding RNA 957;-1.188801453;2.315865227;0.001785209;0.014221289
1730;DIAPH2;up;diaphanous-related formin 2;-1.188420954;3.088494434;0.000153289;0.002712669
80054;CEBPA-AS1;up;CEBPA antisense RNA 1 (head to head);-1.187520823;1.962152599;0.000791132;0.008170128
9700;ESPL1;up;extra spindle pole bodies like 1, separase;-1.183306998;2.2121844;0.002416468;0.017494889
6585;SLIT1;up;slit guidance ligand 1;-1.179534227;2.834887173;0.000196583;0.003150992
9319;TRIP13;up;thyroid hormone receptor interactor 13;-1.173282393;1.57331662;0.007821231;0.040156021
9882;TBC1D4;up;TBC1 domain family, member 4;-1.171619809;6.461619403;8.17E-06;0.000460058
9824;ARHGAP11A;up;Rho GTPase activating protein 11A;-1.166458889;3.409477321;0.000193078;0.003122508
891;CCNB1;up;cyclin B1;-1.163528946;4.053953662;0.001446816;0.012392219
219790;RTKN2;up;rhotekin 2;-1.161574764;1.778007169;0.005415181;0.03129204
NA;LOC100507316;up;NA;-1.161484437;1.811082243;0.001083675;0.010114266
100506142;LOC100506142;up;uncharacterized LOC100506142;-1.160402313;1.438257554;0.00458666;0.027758028
219749;ZNF25;up;zinc finger protein 25;-1.159569445;2.343394581;0.000534217;0.006341301
79896;THNSL1;up;threonine synthase-like 1;-1.158758335;3.255733888;0.000494583;0.006005344
145407;C14orf37;up;chromosome 14 open reading frame 37;-1.155418187;5.755326704;5.76E-06;0.00038004
197257;LDHD;up;lactate dehydrogenase D;-1.154845097;2.808314763;0.000390858;0.005132632
219931;TPCN2;up;two pore segment channel 2;-1.151582575;5.507329892;3.48E-05;0.001064649
7454;WAS;up;Wiskott-Aldrich syndrome;-1.151426232;0.901375944;0.00412738;0.02579925
445;ASS1;up;argininosuccinate synthase 1;-1.151329528;4.616695936;0.002837293;0.0198748
27164;SALL3;up;spalt-like transcription factor 3;-1.150878666;1.486110271;0.008077442;0.041092065
645369;TMEM200C;up;transmembrane protein 200C;-1.147756913;3.356192992;0.000551205;0.006473865
50848;F11R;up;F11 receptor;-1.147173032;5.185212785;1.27E-05;0.00059562
54443;ANLN;up;anillin actin binding protein;-1.146841289;4.344212755;0.000162581;0.002797977
643401;LINC01021;up;long intergenic non-protein coding RNA 1021;-1.144842395;4.25201188;0.000228246;0.003473824
100506757;LINC00629;up;long intergenic non-protein coding RNA 629;-1.143724272;2.761226653;0.00040218;0.005233252
100125556;FAM86JP;up;family with sequence similarity 86, member A pseudogene;-1.143052738;0.541111763;0.007993021;0.040734262
8458;TTF2;up;transcription termination factor, RNA polymerase II;-1.142026728;3.054786972;0.00345212;0.022811132
152687;ZNF595;up;zinc finger protein 595;-1.141234892;2.284233936;0.000580302;0.006690596
3832;KIF11;up;kinesin family member 11;-1.139937271;3.490284621;0.000925217;0.009099854
404201;WDFY3-AS2;up;WDFY3 antisense RNA 2;-1.139769738;1.88448125;0.001456105;0.012434951
3795;KHK;up;ketohexokinase (fructokinase);-1.136310907;1.440610623;0.004648881;0.028005632
101930452;LOC101930452;up;uncharacterized LOC101930452;-1.134562235;0.736479229;0.00463853;0.027966581
148170;CDC42EP5;up;CDC42 effector protein (Rho GTPase binding) 5;-1.132505176;3.185138838;0.000840378;0.008508535
28232;SLCO3A1;up;solute carrier organic anion transporter family, member 3A1;-1.130722761;5.092669194;0.000101447;0.002045638
100132074;FOXO6;up;forkhead box O6;-1.123919691;2.573296192;0.000870759;0.008736597
692072;SNORD5;up;small nucleolar RNA, C/D box 5;-1.122565607;1.194971562;0.003007303;0.020714428
5347;PLK1;up;polo-like kinase 1;-1.121911444;3.635554668;0.000158748;0.002761943
8317;CDC7;up;cell division cycle 7;-1.120572512;2.591981023;0.001804996;0.01427606
91057;CCDC34;up;coiled-coil domain containing 34;-1.120439066;3.072125814;0.000381266;0.005052563
NA;BAI2;up;NA;-1.117517715;7.776611055;3.28E-06;0.000269743
440081;DDX12P;up;DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 12, pseudogene;-1.115648554;3.328760076;0.000138689;0.002515885
646278;PDCD6IPP2;up;PDCD6IP pseudogene 2;-1.114739544;2.506606055;0.000985486;0.009473506
2100;ESR2;up;estrogen receptor 2 (ER beta);-1.111341057;0.393162055;0.008531577;0.042651984
5046;PCSK6;up;proprotein convertase subtilisin/kexin type 6;-1.111268503;3.042202659;0.000800498;0.008249175
25780;RASGRP3;up;RAS guanyl releasing protein 3 (calcium and DAG-regulated);-1.108877714;3.931368005;0.000442244;0.005596603
9132;KCNQ4;up;potassium channel, voltage gated KQT-like subfamily Q, member 4;-1.10657663;1.421915872;0.002234832;0.016485305
285513;GPRIN3;up;GPRIN family member 3;-1.105167298;3.109439465;0.00075832;0.007973668
28999;KLF15;up;Kruppel-like factor 15;-1.103578026;3.224865711;0.000951094;0.009267917
256764;WDR72;up;WD repeat domain 72;-1.103249093;4.711558573;7.36E-05;0.001644376
8913;CACNA1G;up;calcium channel, voltage-dependent, T type, alpha 1G subunit;-1.103023127;6.903119866;2.12E-05;0.000792209
114804;RNF157;up;ring finger protein 157;-1.102942541;3.2716586;0.000297887;0.004234856
101929234;LOC101929234;up;uncharacterized LOC101929234;-1.09965605;0.663471562;0.009766975;0.046945123
57730;ANKRD36B;up;ankyrin repeat domain 36B;-1.092003192;5.542643707;0.000787883;0.008148224
11178;LZTS1;up;leucine zipper, putative tumor suppressor 1;-1.090802462;2.710425907;0.002353718;0.017169555
4257;MGST1;up;microsomal glutathione S-transferase 1;-1.090605693;4.517807912;2.96E-05;0.000958699
80005;DOCK5;up;dedicator of cytokinesis 5;-1.089731784;2.281934836;0.001679572;0.013662332
3213;HOXB3;up;homeobox B3;-1.089595943;5.515386292;4.77E-05;0.001253024
9610;RIN1;up;Ras and Rab interactor 1;-1.089456635;2.191910789;0.001625598;0.013361359
699;BUB1;up;BUB1 mitotic checkpoint serine/threonine kinase;-1.087513352;4.066004889;0.000152239;0.002702735
57406;ABHD6;up;abhydrolase domain containing 6;-1.086945686;3.702524848;0.000130432;0.002427011
4185;ADAM11;up;ADAM metallopeptidase domain 11;-1.08680766;7.778745464;2.72E-05;0.000909256
266727;MDGA1;up;MAM domain containing glycosylphosphatidylinositol anchor 1;-1.086032556;2.747229141;0.004265597;0.026423309
7164;TPD52L1;up;tumor protein D52-like 1;-1.083013482;3.70960478;0.000195341;0.003137407
4846;NOS3;up;nitric oxide synthase 3 (endothelial cell);-1.081331443;3.133978078;0.000500497;0.006055391
55215;FANCI;up;Fanconi anemia, complementation group I;-1.080345256;3.781558982;0.000926332;0.009104626
5596;MAPK4;up;mitogen-activated protein kinase 4;-1.076310967;6.337108122;7.82E-06;0.00044865
NA;GPR64;up;NA;-1.075824462;4.466291148;0.000217936;0.003384038
1123;CHN1;up;chimerin 1;-1.074853796;4.993260249;0.000167133;0.002849532
645513;LOC645513;up;uncharacterized LOC645513;-1.072276497;2.910367504;0.000822375;0.008379071
83857;TMTC1;up;transmembrane and tetratricopeptide repeat containing 1;-1.072258513;5.129311571;5.21E-05;0.001319758
100287227;TIPARP-AS1;up;TIPARP antisense RNA 1;-1.070047611;0.726330783;0.00913191;0.044831634
116028;RMI2;up;RecQ mediated genome instability 2;-1.069565277;2.406817914;0.006882646;0.036828016
9620;CELSR1;up;cadherin, EGF LAG seven-pass G-type receptor 1;-1.068117478;6.483374689;1.08E-05;0.000531313
29902;FAM216A;up;family with sequence similarity 216, member A;-1.067483481;3.728921656;0.00024947;0.003733791
81930;KIF18A;up;kinesin family member 18A;-1.067317093;1.975753676;0.007703696;0.039705551
55601;DDX60;up;DEAD (Asp-Glu-Ala-Asp) box polypeptide 60;-1.066765068;2.479296101;0.002184006;0.016234635
22974;TPX2;up;TPX2, microtubule-associated;-1.065123316;4.883363761;0.000801635;0.00825501
142;PARP1;up;poly (ADP-ribose) polymerase 1;-1.064871428;7.273447878;1.03E-05;0.000521425
645332;FAM86C2P;up;family with sequence similarity 86, member A pseudogene;-1.06237259;2.37362022;0.007234525;0.038041037
146956;EME1;up;essential meiotic structure-specific endonuclease 1;-1.062360588;1.745763618;0.002303593;0.016872006
83478;ARHGAP24;up;Rho GTPase activating protein 24;-1.060881777;2.11664224;0.003329579;0.022245406
1075;CTSC;up;cathepsin C;-1.059297268;6.426124152;3.74E-05;0.001103888
91522;COL23A1;up;collagen, type XXIII, alpha 1;-1.059280612;5.509987922;2.24E-05;0.000815808
727936;GXYLT2;up;glucoside xylosyltransferase 2;-1.05887217;2.899032585;0.000402102;0.005233252
64087;MCCC2;up;methylcrotonoyl-CoA carboxylase 2 (beta);-1.058847455;5.659938904;3.30E-05;0.001037545
144404;TMEM120B;up;transmembrane protein 120B;-1.057091845;6.453860478;5.33E-06;0.00036383
57578;UNC79;up;unc-79 homolog (C. elegans);-1.055934266;4.281204056;0.000462217;0.005746113
65982;ZSCAN18;up;zinc finger and SCAN domain containing 18;-1.055475343;6.276228298;6.74E-06;0.000409214
1894;ECT2;up;epithelial cell transforming 2;-1.053582489;4.420400469;6.80E-05;0.001570766
84251;SGIP1;up;SH3-domain GRB2-like (endophilin) interacting protein 1;-1.05153692;2.803772299;0.003098782;0.021193088
7083;TK1;up;thymidine kinase 1, soluble;-1.04938874;1.453561364;0.00337778;0.022505043
637;BID;up;BH3 interacting domain death agonist;-1.046360474;2.966326717;0.000498086;0.006036322
157638;FAM84B;up;family with sequence similarity 84, member B;-1.046293673;6.750189872;0.000570424;0.006618932
57685;CACHD1;up;cache domain containing 1;-1.046076642;6.070064477;6.08E-05;0.001454459
8543;LMO4;up;LIM domain only 4;-1.044713395;6.530804118;3.12E-05;0.000999813
84561;SLC12A8;up;solute carrier family 12, member 8;-1.042978749;0.970924777;0.005775662;0.032675452
219;ALDH1B1;up;aldehyde dehydrogenase 1 family, member B1;-1.038053534;4.447336232;0.000197043;0.003154867
9074;CLDN6;up;claudin 6;-1.035850834;6.972836015;0.0005848;0.006705026
4522;MTHFD1;up;methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase;-1.033043747;5.290920064;6.06E-05;0.001452867
80164;PRR36;up;proline rich 36;-1.030903786;2.511903848;0.003341599;0.022305094
400322;HERC2P2;up;hect domain and RLD 2 pseudogene 2;-1.029633967;7.585658853;3.64E-06;0.000288929
10715;CERS1;up;ceramide synthase 1;-1.02905953;2.437854462;0.001134539;0.010461205
100506123;LOC100506123;up;uncharacterized LOC100506123;-1.02806325;6.187562857;0.000542154;0.006409214
100505761;RPARP-AS1;up;RPARP antisense RNA 1;-1.027920483;3.252494632;0.000558434;0.006532233
55061;SUSD4;up;sushi domain containing 4;-1.027080687;1.456179698;0.006740416;0.036254811
23433;RHOQ;up;ras homolog family member Q;-1.023696478;7.843784063;6.03E-05;0.001451139
5588;PRKCQ;up;protein kinase C, theta;-1.021880269;1.938600193;0.002313031;0.016932557
1462;VCAN;up;versican;-1.016176129;11.66405802;3.70E-05;0.001102816
90673;PPP1R3E;up;protein phosphatase 1, regulatory subunit 3E;-1.015321862;5.162414344;1.97E-05;0.000756141
81035;COLEC12;up;collectin sub-family member 12;-1.013891527;5.965391007;0.000185727;0.003044611
10615;SPAG5;up;sperm associated antigen 5;-1.01281688;4.045120325;0.001040348;0.009818117
239;ALOX12;up;arachidonate 12-lipoxygenase;-1.012330426;2.157745499;0.007217634;0.0380155
1164;CKS2;up;CDC28 protein kinase regulatory subunit 2;-1.012247919;2.964334848;0.00040484;0.005258924
10188;TNK2;up;tyrosine kinase, non-receptor, 2;-1.006079131;6.411487932;6.79E-06;0.000410599
27293;SMPDL3B;up;sphingomyelin phosphodiesterase, acid-like 3B;-1.005267165;1.915342112;0.004239613;0.026313463
100996539;ITPR1-AS1;up;ITPR1 antisense RNA 1 (head to head);-1.004451764;0.975757819;0.004794191;0.028606854
79682;CENPU;up;centromere protein U;-1.002714834;2.236452988;0.005235128;0.030519954
57664;PLEKHA4;up;pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 4;-1.002465125;4.387624665;4.55E-05;0.001210371
2039;DMTN;up;dematin actin binding protein;-1.001057996;0.88727127;0.007249898;0.038096999
54058;C21orf58;up;chromosome 21 open reading frame 58;-1.000067733;3.644245769;0.000208432;0.003297781
51360;MBTPS2;down;membrane-bound transcription factor peptidase, site 2;1.003218256;6.024832759;4.66E-06;0.000333624
51676;ASB2;down;ankyrin repeat and SOCS box containing 2;1.004744851;8.658443022;3.91E-05;0.001122022
55829;VIMP;down;VCP-interacting membrane selenoprotein;1.006033248;5.092652383;2.09E-05;0.000788248
79957;PAQR6;down;progestin and adipoQ receptor family member VI;1.006043524;5.138742367;3.40E-05;0.001060475
29995;LMCD1;down;LIM and cysteine-rich domains 1;1.00859151;3.366109519;0.000237606;0.003600946
9213;XPR1;down;xenotropic and polytropic retrovirus receptor 1;1.008763143;8.917547732;3.07E-05;0.000987885
55243;KIRREL;down;kin of IRRE like (Drosophila);1.009683074;6.034640656;2.11E-05;0.000792092
84230;LRRC8C;down;leucine rich repeat containing 8 family, member C;1.011181509;4.90760175;3.54E-05;0.001074251
284217;LAMA1;down;laminin, alpha 1;1.012036105;8.273548456;2.53E-06;0.000229711
94241;TP53INP1;down;tumor protein p53 inducible nuclear protein 1;1.012457692;7.246129227;0.000209994;0.003301902
3037;HAS2;down;hyaluronan synthase 2;1.017942643;5.899194108;9.72E-06;0.000502062
387914;SHISA2;down;shisa family member 2;1.018822945;4.770043532;7.20E-05;0.001625413
1821;DRP2;down;dystrophin related protein 2;1.019719192;2.066097582;0.00213254;0.015958727
961;CD47;down;CD47 molecule;1.020609521;6.873589408;0.000177376;0.002953713
51733;UPB1;down;ureidopropionase, beta;1.021572551;2.797949307;0.000689122;0.007496937
643314;KIAA0754;down;KIAA0754;1.022335572;4.224104389;6.29E-05;0.001495379
22996;TTC39A;down;tetratricopeptide repeat domain 39A;1.027998225;4.177483062;0.000214391;0.00334589
90161;HS6ST2;down;heparan sulfate 6-O-sulfotransferase 2;1.028647758;5.410582637;0.000838169;0.008492115
4131;MAP1B;down;microtubule-associated protein 1B;1.029797586;7.266145444;2.85E-05;0.000934825
101929550;LOC101929550;down;uncharacterized LOC101929550;1.033456351;2.897147985;0.001268195;0.011353293
8933;FAM127A;down;family with sequence similarity 127, member A;1.034605272;8.193025276;2.70E-06;0.000240944
29993;PACSIN1;down;protein kinase C and casein kinase substrate in neurons 1;1.036582734;5.671892214;6.81E-05;0.001570799
9926;LPGAT1;down;lysophosphatidylglycerol acyltransferase 1;1.037998047;7.525240693;9.04E-06;0.000486276
3742;KCNA6;down;potassium channel, voltage gated shaker related subfamily A, member 6;1.03899269;4.004607955;0.000131225;0.002432367
3397;ID1;down;inhibitor of DNA binding 1, dominant negative helix-loop-helix protein;1.040625831;6.682573355;0.000221468;0.00341363
92346;C1orf105;down;chromosome 1 open reading frame 105;1.041799229;4.453391899;8.05E-05;0.001725883
10252;SPRY1;down;sprouty RTK signaling antagonist 1;1.042075383;4.854997001;0.000726228;0.007766127
9455;HOMER2;down;homer scaffolding protein 2;1.044094252;4.002039523;7.14E-05;0.001620976
1410;CRYAB;down;crystallin, alpha B;1.044792779;6.22925485;0.00213187;0.015958727
9456;HOMER1;down;homer scaffolding protein 1;1.044848664;6.244876991;2.01E-05;0.00076374
1674;DES;down;desmin;1.044911558;6.776791321;0.001040123;0.009818117
1600;DAB1;down;Dab, reelin signal transducer, homolog 1 (Drosophila);1.045732513;5.229354659;3.93E-05;0.001122022
116931;MED12L;down;mediator complex subunit 12-like;1.046379668;3.139328848;0.001657937;0.013567575
50515;CHST11;down;carbohydrate (chondroitin 4) sulfotransferase 11;1.046418683;5.608579607;0.000140114;0.002535373
51129;ANGPTL4;down;angiopoietin-like 4;1.048698267;0.416768028;0.010521839;0.049581477
3777;KCNK3;down;potassium channel, two pore domain subfamily K, member 3;1.049443624;2.561253438;0.000787441;0.008148224
11098;PRSS23;down;protease, serine, 23;1.052194992;6.118907307;7.80E-05;0.001710966
7127;TNFAIP2;down;tumor necrosis factor, alpha-induced protein 2;1.053780571;2.658578714;0.008555058;0.042725053
2321;FLT1;down;fms-related tyrosine kinase 1;1.054424892;5.717605493;8.32E-05;0.001763726
7461;CLIP2;down;CAP-GLY domain containing linker protein 2;1.054943004;3.789283179;0.000776709;0.008073085
58476;TP53INP2;down;tumor protein p53 inducible nuclear protein 2;1.055233372;6.052252704;4.11E-06;0.00030767
23108;RAP1GAP2;down;RAP1 GTPase activating protein 2;1.057248267;2.706106568;0.00054382;0.006413171
3574;IL7;down;interleukin 7;1.057273067;1.925586023;0.001741082;0.014000312
8534;CHST1;down;carbohydrate (keratan sulfate Gal-6) sulfotransferase 1;1.057559773;1.662608711;0.002576248;0.01840286
1948;EFNB2;down;ephrin-B2;1.061036009;4.140755262;0.000428251;0.005490774
26230;TIAM2;down;T-cell lymphoma invasion and metastasis 2;1.062543215;4.004942251;0.000183279;0.003014617
4778;NFE2;down;nuclear factor, erythroid 2;1.062595742;2.894466759;0.000596845;0.006804039
6196;RPS6KA2;down;ribosomal protein S6 kinase, 90kDa, polypeptide 2;1.063716245;5.999773933;3.53E-05;0.001074039
30845;EHD3;down;EH-domain containing 3;1.070374471;6.455709439;0.000407693;0.005291227
57586;SYT13;down;synaptotagmin XIII;1.07169879;1.37175353;0.00991301;0.047520658
488;ATP2A2;down;ATPase, Ca++ transporting, cardiac muscle, slow twitch 2;1.073858909;11.15620029;3.18E-05;0.001011899
441631;TSPAN11;down;tetraspanin 11;1.074037527;3.659281424;0.000109193;0.002144987
55466;DNAJA4;down;DnaJ (Hsp40) homolog, subfamily A, member 4;1.074046466;5.441746421;0.000107703;0.002132508
1160;CKMT2;down;creatine kinase, mitochondrial 2 (sarcomeric);1.074272805;5.248307434;7.50E-05;0.001665233
10602;CDC42EP3;down;CDC42 effector protein (Rho GTPase binding) 3;1.074942474;6.4342001;4.91E-05;0.001278532
101927167;GATA2-AS1;down;GATA2 antisense RNA 1;1.076726371;2.861452167;0.000519311;0.006223078
7171;TPM4;down;tropomyosin 4;1.082469178;7.830964719;1.35E-06;0.000155202
1942;EFNA1;down;ephrin-A1;1.083009812;5.690976133;1.73E-05;0.000716793
9369;NRXN3;down;neurexin 3;1.084271311;2.406113328;0.002043121;0.015485467
201191;SAMD14;down;sterile alpha motif domain containing 14;1.086721325;1.389154864;0.003406632;0.022632384
56967;C14orf132;down;chromosome 14 open reading frame 132;1.08983284;3.995621969;5.84E-05;0.00141801
340526;RGAG4;down;retrotransposon gag domain containing 4;1.091400166;6.657063411;2.59E-05;0.000883717
388561;ZNF761;down;zinc finger protein 761;1.092581222;5.770965132;6.44E-06;0.000403067
100288346;NCAM1-AS1;down;NCAM1 antisense RNA1;1.093249203;1.604838055;0.004178711;0.026046636
57458;TMCC3;down;transmembrane and coiled-coil domain family 3;1.094240374;1.819879212;0.003775162;0.024216121
4208;MEF2C;down;myocyte enhancer factor 2C;1.095264773;8.129303345;1.00E-05;0.000512177
7287;TULP1;down;tubby like protein 1;1.096559218;4.049345587;0.000155198;0.002723122
2845;GPR22;down;G protein-coupled receptor 22;1.096630799;1.85534457;0.003130777;0.02130498
344558;SH3RF3;down;SH3 domain containing ring finger 3;1.097410294;1.639527481;0.003705996;0.023888224
81563;C1orf21;down;chromosome 1 open reading frame 21;1.097855747;6.343491837;6.66E-05;0.001553702
56603;CYP26B1;down;cytochrome P450, family 26, subfamily B, polypeptide 1;1.099904949;0.728862797;0.007912223;0.040465127
122786;FRMD6;down;FERM domain containing 6;1.100180452;4.525254525;4.41E-05;0.001190055
339366;ADAMTSL5;down;ADAMTS-like 5;1.102133295;3.753452927;0.000769025;0.008022686
64101;LRRC4;down;leucine rich repeat containing 4;1.106660051;5.85460515;3.91E-05;0.001122022
144699;FBXL14;down;F-box and leucine-rich repeat protein 14;1.107406338;2.346236628;0.000803965;0.008264892
55824;PAG1;down;phosphoprotein membrane anchor with glycosphingolipid microdomains 1;1.108153203;4.780587606;1.31E-05;0.000601611
9118;INA;down;internexin neuronal intermediate filament protein, alpha;1.108494764;1.105203607;0.004976293;0.02935424
116442;RAB39B;down;RAB39B, member RAS oncogene family;1.108846843;1.019403149;0.006914105;0.036900747
58494;JAM2;down;junctional adhesion molecule 2;1.109467538;1.385626288;0.002608129;0.018593852
23406;COTL1;down;coactosin-like F-actin binding protein 1;1.10959783;4.745964422;0.000205776;0.003276549
100506627;DCDC5;down;doublecortin domain containing 5;1.11162346;1.140147865;0.010221994;0.048551114
4320;MMP11;down;matrix metallopeptidase 11;1.111675243;3.260683631;0.000373165;0.00500064
101928857;CTD-3080P12.3;down;uncharacterized LOC101928857;1.111787475;2.451789427;0.000624494;0.007008521
4645;MYO5B;down;myosin VB;1.111806292;3.083167874;0.000392484;0.005139973
148398;SAMD11;down;sterile alpha motif domain containing 11;1.112472265;5.127144538;3.73E-05;0.001103888
64780;MICAL1;down;microtubule associated monooxygenase, calponin and LIM domain containing 1;1.115482;4.073943357;0.000109719;0.002152404
4824;NKX3-1;down;NK3 homeobox 1;1.115962948;4.190657483;8.25E-05;0.001755795
728392;LOC728392;down;uncharacterized LOC728392;1.117361279;4.562735633;8.30E-05;0.001761931
333;APLP1;down;amyloid beta (A4) precursor-like protein 1;1.121425421;3.914675302;4.18E-05;0.001162043
440910;LOC440910;down;uncharacterized LOC440910;1.122594042;4.486801796;0.000208328;0.003297781
29028;ATAD2;down;ATPase family, AAA domain containing 2;1.12400896;7.151423977;9.42E-05;0.001926461
26509;MYOF;down;myoferlin;1.12496021;8.051539827;1.33E-06;0.00015367
1741;DLG3;down;discs, large homolog 3 (Drosophila);1.125258094;7.135970831;1.42E-06;0.000161501
4135;MAP6;down;microtubule-associated protein 6;1.126879521;1.599714891;0.002373994;0.017267025
8483;CILP;down;cartilage intermediate layer protein, nucleotide pyrophosphohydrolase;1.127783434;1.050613167;0.004918735;0.02908592
23550;PSD4;down;pleckstrin and Sec7 domain containing 4;1.127892015;2.682496939;0.000869381;0.008728825
84557;MAP1LC3A;down;microtubule-associated protein 1 light chain 3 alpha;1.12928659;3.734015331;0.000231213;0.003511429
80333;KCNIP4;down;Kv channel interacting protein 4;1.129460895;3.731858413;0.001680151;0.013662332
1277;COL1A1;down;collagen, type I, alpha 1;1.130979532;9.488597142;2.36E-05;0.000846316
8728;ADAM19;down;ADAM metallopeptidase domain 19;1.131634485;5.90185536;0.001306202;0.011585928
55853;IDI2-AS1;down;IDI2 antisense RNA 1;1.133770868;1.976065381;0.00851212;0.042609095
400043;LOC400043;down;uncharacterized LOC400043;1.134995217;2.867764228;0.000491386;0.005995326
79596;RNF219;down;ring finger protein 219;1.13574477;4.906469242;1.85E-05;0.000735059
399474;TMEM200B;down;transmembrane protein 200B;1.135769131;5.918470525;0.001573127;0.013078917
1271;CNTFR;down;ciliary neurotrophic factor receptor;1.135842595;6.271438085;1.45E-06;0.000164074
7448;VTN;down;vitronectin;1.137237815;2.807073871;0.00293964;0.020355036
9353;SLIT2;down;slit guidance ligand 2;1.138741217;7.771260447;7.95E-06;0.000454594
3824;KLRD1;down;killer cell lectin-like receptor subfamily D, member 1;1.138789023;1.124826074;0.003599134;0.023428612
30811;HUNK;down;hormonally up-regulated Neu-associated kinase;1.138804897;3.395080417;0.00075638;0.007959051
51466;EVL;down;Enah/Vasp-like;1.139703089;5.166062118;1.29E-05;0.00059873
151009;LINC01106;down;long intergenic non-protein coding RNA 1106;1.141688016;2.643934817;0.000554357;0.006505591
114088;TRIM9;down;tripartite motif containing 9;1.142592166;4.603695108;0.00036491;0.004921518
154091;SLC2A12;down;solute carrier family 2 (facilitated glucose transporter), member 12;1.142615904;4.127086286;0.000657161;0.007252427
84848;MIR503HG;down;MIR503 host gene;1.144564162;2.051315721;0.001834555;0.014446618
26032;SUSD5;down;sushi domain containing 5;1.146115762;3.254975875;0.004363074;0.026793807
51363;CHST15;down;carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15;1.146261071;1.253394134;0.00221881;0.016408981
5028;P2RY1;down;purinergic receptor P2Y, G-protein coupled, 1;1.149306698;3.800230094;0.001417095;0.012217269
646762;LOC646762;down;uncharacterized LOC646762;1.149481092;6.49816597;0.000117265;0.002247452
7280;TUBB2A;down;tubulin, beta 2A class IIa;1.150841679;3.924772083;0.00014198;0.002562725
2977;GUCY1A2;down;guanylate cyclase 1, soluble, alpha 2;1.152016237;1.308322286;0.001062441;0.009987497
123688;HYKK;down;hydroxylysine kinase;1.152589477;0.574157592;0.008483669;0.042515385
154796;AMOT;down;angiomotin;1.15369274;5.305425152;2.00E-05;0.00076374
55203;LGI2;down;leucine-rich repeat LGI family, member 2;1.153787057;7.172520195;0.000112525;0.002192787
55714;TENM3;down;teneurin transmembrane protein 3;1.155890299;6.380317602;9.28E-06;0.000493074
126017;ZNF813;down;zinc finger protein 813;1.156030879;4.114000485;6.36E-05;0.001502862
23645;PPP1R15A;down;protein phosphatase 1, regulatory subunit 15A;1.158157832;6.238539712;6.38E-05;0.001504364
51214;IGF2-AS;down;IGF2 antisense RNA;1.160694003;1.494598748;0.007233729;0.038041037
54566;EPB41L4B;down;erythrocyte membrane protein band 4.1 like 4B;1.162606743;1.676418404;0.001203109;0.010905673
646300;COL6A4P2;down;collagen, type VI, alpha 4 pseudogene 2;1.16325416;6.159018458;4.38E-05;0.001188112
10435;CDC42EP2;down;CDC42 effector protein (Rho GTPase binding) 2;1.163722349;1.195856065;0.004460332;0.027175506
120114;FAT3;down;FAT atypical cadherin 3;1.16461349;4.893847332;1.72E-05;0.00071565
85352;KIAA1644;down;KIAA1644;1.165495957;2.94417761;0.000109063;0.002144987
1264;CNN1;down;calponin 1, basic, smooth muscle;1.167292436;7.397612152;2.38E-06;0.0002265
127294;MYOM3;down;myomesin 3;1.17003;2.41414108;0.000493317;0.006003688
406990;MIR208A;down;microRNA 208a;1.170209149;2.535766963;0.001085379;0.010117608
7832;BTG2;down;BTG family, member 2;1.173620433;6.061079819;0.000114415;0.002221098
7145;TNS1;down;tensin 1;1.175416836;6.309603389;1.80E-05;0.000727866
54329;GPR85;down;G protein-coupled receptor 85;1.176259089;0.456853399;0.006657599;0.035969942
3752;KCND3;down;potassium channel, voltage gated Shal related subfamily D, member 3;1.176814739;0.253409964;0.003966797;0.025121313
3696;ITGB8;down;integrin, beta 8;1.177123324;1.253277421;0.003526383;0.023206393
90993;CREB3L1;down;cAMP responsive element binding protein 3-like 1;1.179428609;2.810411296;0.000557325;0.006524787
1316;KLF6;down;Kruppel-like factor 6;1.180021609;5.392371557;1.91E-05;0.000740956
51101;ZC2HC1A;down;zinc finger, C2HC-type containing 1A;1.18153087;7.235648686;8.14E-07;0.000116506
84439;HHIPL1;down;HHIP-like 1;1.181535052;0.920657309;0.006397565;0.035069763
2354;FOSB;down;FBJ murine osteosarcoma viral oncogene homolog B;1.181962292;3.586651068;2.46E-05;0.00087104
23052;ENDOD1;down;endonuclease domain containing 1;1.181981658;1.795667426;0.00403106;0.025383737
400258;C14orf180;down;chromosome 14 open reading frame 180;1.182122327;4.304732104;3.57E-05;0.001075197
150946;GAREML;down;GRB2 associated, regulator of MAPK1-like;1.182739941;1.707011405;0.001004159;0.009589257
10409;BASP1;down;brain abundant, membrane attached signal protein 1;1.185471627;6.067203681;3.31E-06;0.000270093
5222;PGA5;down;pepsinogen 5, group I (pepsinogen A);1.185583858;2.089095062;0.001186405;0.010801666
1903;S1PR3;down;sphingosine-1-phosphate receptor 3;1.186359374;5.860553673;1.68E-06;0.000176472
10475;TRIM38;down;tripartite motif containing 38;1.187732009;0.772935406;0.00494196;0.029187442
5587;PRKD1;down;protein kinase D1;1.188654614;4.350042823;3.93E-05;0.001122022
1136;CHRNA3;down;cholinergic receptor, nicotinic, alpha 3 (neuronal);1.188976987;1.80925882;0.000958808;0.00930366
187;APLNR;down;apelin receptor;1.189565924;4.319268851;0.00106693;0.010010174
NA;LINC00883;down;NA;1.190357305;3.960704975;6.45E-05;0.001512809
23148;NACAD;down;NAC alpha domain containing;1.194366634;1.688307976;0.001573248;0.013078917
2892;GRIA3;down;glutamate receptor, ionotropic, AMPA 3;1.19461862;5.89792026;1.17E-05;0.000563896
53918;PELO;down;pelota homolog (Drosophila);1.199088344;4.877127506;0.000107433;0.002130689
491;ATP2B2;down;ATPase, Ca++ transporting, plasma membrane 2;1.201688204;3.327580472;0.002865041;0.019994338
64131;XYLT1;down;xylosyltransferase I;1.20618498;4.632351237;8.12E-06;0.000460058
11141;IL1RAPL1;down;interleukin 1 receptor accessory protein-like 1;1.207445618;0.194625492;0.010282459;0.048758212
79827;CLMP;down;CXADR-like membrane protein;1.208843358;0.205727425;0.008863734;0.043817432
286;ANK1;down;ankyrin 1, erythrocytic;1.209071017;4.180004096;0.000284688;0.004105697
219527;LRRC55;down;leucine rich repeat containing 55;1.210085681;1.503053091;0.003546883;0.02328533
8761;PABPC4;down;poly(A) binding protein, cytoplasmic 4 (inducible form);1.214940806;7.351516203;1.58E-05;0.00068674
650;BMP2;down;bone morphogenetic protein 2;1.21519921;7.261604646;5.94E-05;0.001440658
7043;TGFB3;down;transforming growth factor, beta 3;1.215583397;4.719063722;1.34E-05;0.000611354
7447;VSNL1;down;visinin-like 1;1.215790835;3.152851878;7.79E-05;0.001710966
63901;FAM111A;down;family with sequence similarity 111, member A;1.216151622;1.900785464;0.003976369;0.025137206
8911;CACNA1I;down;calcium channel, voltage-dependent, T type, alpha 1I subunit;1.227897601;1.216578621;0.001895613;0.014815882
9509;ADAMTS2;down;ADAM metallopeptidase with thrombospondin type 1 motif, 2;1.22865479;3.473246948;0.000392342;0.005139973
165215;FAM171B;down;family with sequence similarity 171, member B;1.229206504;0.191700635;0.009271826;0.045236175
10873;ME3;down;malic enzyme 3, NADP(+)-dependent, mitochondrial;1.231006207;2.267654999;0.002683814;0.019048886
6678;SPARC;down;secreted protein, acidic, cysteine-rich (osteonectin);1.232853612;7.975913366;7.56E-07;0.000110438
79933;SYNPO2L;down;synaptopodin 2-like;1.233577756;8.180181956;7.01E-05;0.001603627
5733;PTGER3;down;prostaglandin E receptor 3 (subtype EP3);1.23664477;3.23217483;8.53E-05;0.00179431
200010;SLC5A9;down;solute carrier family 5 (sodium/sugar cotransporter), member 9;1.236704506;3.349394414;0.000322626;0.004472219
148756;OVAAL;down;ovarian adenocarcinoma amplified long non-coding RNA;1.237925613;1.090868957;0.00331846;0.022191627
89927;C16orf45;down;chromosome 16 open reading frame 45;1.239384073;3.187356784;0.000160639;0.002778125
30846;EHD2;down;EH-domain containing 2;1.241564181;2.313868337;0.000999054;0.009572119
NA;AGPAT9;down;NA;1.242513284;3.243324139;0.00105507;0.009937587
8821;INPP4B;down;inositol polyphosphate-4-phosphatase type II B;1.244332101;2.960589607;0.000637336;0.007115527
9162;DGKI;down;diacylglycerol kinase, iota;1.251127497;7.31458213;1.77E-06;0.000181228
1837;DTNA;down;dystrobrevin, alpha;1.251262045;4.598570397;4.17E-05;0.001162043
51330;TNFRSF12A;down;tumor necrosis factor receptor superfamily, member 12A;1.253648812;5.528336447;1.54E-05;0.000674938
2116;ETV2;down;ets variant 2;1.255078627;0.079715592;0.009484995;0.04597526
54716;SLC6A20;down;solute carrier family 6 (proline IMINO transporter), member 20;1.260492061;4.484261161;0.000281634;0.004071868
1191;CLU;down;clusterin;1.260848242;3.774179748;0.000409702;0.005307766
6261;RYR1;down;ryanodine receptor 1 (skeletal);1.260983983;6.371105946;8.35E-07;0.000117207
101927075;FGF10-AS1;down;FGF10 antisense RNA 1;1.261457016;1.66423375;0.001029788;0.009760826
64881;PCDH20;down;protocadherin 20;1.262880221;3.410128264;0.000521835;0.006240396
3743;KCNA7;down;potassium channel, voltage gated shaker related subfamily A, member 7;1.264546632;4.615563168;0.000130869;0.002429796
4124;MAN2A1;down;mannosidase, alpha, class 2A, member 1;1.26579341;5.642474114;1.38E-05;0.000621946
100130705;LOC100130705;down;uncharacterized LOC100130705;1.268213167;1.122664255;0.002229309;0.016469776
26053;AUTS2;down;autism susceptibility candidate 2;1.271206215;7.015005852;7.00E-06;0.000418048
2273;FHL1;down;four and a half LIM domains 1;1.274070784;6.16416924;4.87E-06;0.000343143
79930;DOK3;down;docking protein 3;1.278796719;0.937645945;0.001687012;0.013687326
55553;SOX6;down;SRY (sex determining region Y)-box 6;1.279124502;2.40048754;0.002153748;0.016067537
56849;TCEAL7;down;transcription elongation factor A (SII)-like 7;1.279670397;3.06903772;7.49E-05;0.001665233
427;ASAH1;down;N-acylsphingosine amidohydrolase (acid ceramidase) 1;1.28081209;7.750615819;6.47E-07;0.00010444
2781;GNAZ;down;guanine nucleotide binding protein (G protein), alpha z polypeptide;1.28095305;1.573829398;0.000843557;0.008534743
22885;ABLIM3;down;actin binding LIM protein family, member 3;1.28096171;2.656710334;0.000166198;0.00283931
338758;LINC00936;down;long intergenic non-protein coding RNA 936;1.281413388;2.343126121;0.000949151;0.009259662
2740;GLP1R;down;glucagon-like peptide 1 receptor;1.291068729;-0.079212924;0.007224588;0.038030989
51655;RASD1;down;RAS, dexamethasone-induced 1;1.294793936;5.19584861;0.00039036;0.005130747
4739;NEDD9;down;neural precursor cell expressed, developmentally down-regulated 9;1.303663699;5.149699693;0.001973694;0.01517076
22809;ATF5;down;activating transcription factor 5;1.304200735;3.078207025;0.000319636;0.004469338
643236;TMEM72;down;transmembrane protein 72;1.306937586;2.276533886;0.00043536;0.005538496
144811;LACC1;down;laccase (multicopper oxidoreductase) domain containing 1;1.30936134;3.017985333;0.000157009;0.002741594
84443;FRMPD3;down;FERM and PDZ domain containing 3;1.310988559;1.796786507;0.000564545;0.006577114
26548;ITGB1BP2;down;integrin beta 1 binding protein (melusin) 2;1.311643103;6.586738658;6.69E-05;0.001558053
142689;ASB12;down;ankyrin repeat and SOCS box containing 12;1.312370876;1.088909056;0.00256414;0.018343562
10742;RAI2;down;retinoic acid induced 2;1.313276267;0.967805744;0.002539363;0.018211361
94122;SYTL5;down;synaptotagmin-like 5;1.313700325;5.071589693;0.000546457;0.00643902
5654;HTRA1;down;HtrA serine peptidase 1;1.31401514;8.278871376;2.94E-06;0.000257991
59269;HIVEP3;down;human immunodeficiency virus type I enhancer binding protein 3;1.316135237;0.910804762;0.006433852;0.035155191
93664;CADPS2;down;Ca++-dependent secretion activator 2;1.317907732;5.458914859;0.000312295;0.004383652
102723167;MIR133A1HG;down;MIR133A1 host gene (non-protein coding);1.318336934;5.047681957;0.00372541;0.02398129
5947;RBP1;down;retinol binding protein 1, cellular;1.319040006;6.188340031;3.41E-06;0.000276299
10865;ARID5A;down;AT rich interactive domain 5A (MRF1-like);1.3196097;2.165223604;0.00022841;0.003473824
114571;SLC22A9;down;solute carrier family 22 (organic anion transporter), member 9;1.319919846;0.342972092;0.003409416;0.022632384
5067;CNTN3;down;contactin 3 (plasmacytoma associated);1.320547528;1.717705127;0.001889116;0.014786219
54504;CPVL;down;carboxypeptidase, vitellogenic-like;1.327831644;6.536177432;1.19E-06;0.000148238
148281;SYT6;down;synaptotagmin VI;1.328672499;2.021236907;0.0014319;0.012300899
8140;SLC7A5;down;solute carrier family 7 (amino acid transporter light chain, L system), member 5;1.337327138;4.758936808;0.000175017;0.002925317
5362;PLXNA2;down;plexin A2;1.33752813;6.015110518;1.07E-05;0.000530704
2791;GNG11;down;guanine nucleotide binding protein (G protein), gamma 11;1.34106659;4.095305244;8.70E-05;0.001820147
101928283;LOC101928283;down;uncharacterized LOC101928283;1.341451478;0.834051985;0.007787789;0.039998529
340591;CA5BP1;down;carbonic anhydrase VB pseudogene 1;1.343383782;3.544515925;0.000106118;0.002109521
1375;CPT1B;down;carnitine palmitoyltransferase 1B (muscle);1.343825948;0.56892525;0.003439174;0.022746373
345630;FBLL1;down;fibrillarin-like 1;1.347254842;0.557327491;0.002839439;0.019880199
10512;SEMA3C;down;sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C;1.349860761;6.781044359;7.45E-06;0.000432362
7173;TPO;down;thyroid peroxidase;1.350388245;2.152875147;0.001519026;0.012783126
6387;CXCL12;down;chemokine (C-X-C motif) ligand 12;1.351243707;5.550918956;9.53E-06;0.000499367
26050;SLITRK5;down;SLIT and NTRK-like family, member 5;1.353891499;-0.32910555;0.006332914;0.03485393
23767;FLRT3;down;fibronectin leucine rich transmembrane protein 3;1.355641694;3.980018836;3.20E-05;0.001011899
1601;DAB2;down;Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila);1.355890446;3.947619707;5.58E-05;0.001374238
8614;STC2;down;stanniocalcin 2;1.355990241;7.266393896;3.12E-05;0.000999813
30010;NXPH1;down;neurexophilin 1;1.358171112;3.266079311;0.000194269;0.003137233
3897;L1CAM;down;L1 cell adhesion molecule;1.364657699;1.112450946;0.001420653;0.012240642
54331;GNG2;down;guanine nucleotide binding protein (G protein), gamma 2;1.365843325;2.177302142;0.000651413;0.007216958
7035;TFPI;down;tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor);1.367661074;3.121821672;0.000189553;0.003086219
65997;RASL11B;down;RAS-like, family 11, member B;1.372930132;5.885456497;0.001614055;0.013319641
3707;ITPKB;down;inositol-trisphosphate 3-kinase B;1.378615102;2.016749002;0.00027095;0.003941043
4881;NPR1;down;natriuretic peptide receptor 1;1.379986089;1.156080845;0.009555461;0.046204968
3988;LIPA;down;lipase A, lysosomal acid, cholesterol esterase;1.380116077;3.858472631;1.49E-05;0.000658433
1128;CHRM1;down;cholinergic receptor, muscarinic 1;1.382071386;0.299501329;0.003075257;0.021072067
1647;GADD45A;down;growth arrest and DNA-damage-inducible, alpha;1.383646481;6.018040404;1.01E-05;0.000514552
645166;LOC645166;down;lymphocyte-specific protein 1 pseudogene;1.385727411;0.630798843;0.002899884;0.020166679
2009;EML1;down;echinoderm microtubule associated protein like 1;1.387186885;3.373625104;4.32E-05;0.001182676
56961;SHD;down;Src homology 2 domain containing transforming protein D;1.387217884;7.366761455;1.01E-06;0.000133709
23208;SYT11;down;synaptotagmin XI;1.38860394;3.440270674;0.000262071;0.003842823
5580;PRKCD;down;protein kinase C, delta;1.390810999;1.52768563;0.000513844;0.006180659
401321;LINC00997;down;long intergenic non-protein coding RNA 997;1.391292866;6.742177149;6.23E-06;0.000396642
54510;PCDH18;down;protocadherin 18;1.392765706;3.624141179;0.000209222;0.003298721
8613;PPAP2B;down;phosphatidic acid phosphatase type 2B;1.39429197;5.550602603;5.11E-06;0.000351617
57460;PPM1H;down;protein phosphatase, Mg2+/Mn2+ dependent, 1H;1.396138419;6.246205756;2.99E-06;0.000259987
7424;VEGFC;down;vascular endothelial growth factor C;1.3981801;2.876648794;0.000794834;0.008196659
27163;NAAA;down;N-acylethanolamine acid amidase;1.398424324;2.565135203;0.000126434;0.002380195
102724105;ZNF528-AS1;down;ZNF528 antisense RNA 1;1.398442306;2.398914407;0.00036441;0.004921518
152007;GLIPR2;down;GLI pathogenesis-related 2;1.399328306;3.002441797;5.26E-05;0.001322875
490;ATP2B1;down;ATPase, Ca++ transporting, plasma membrane 1;1.400289101;6.691956893;1.26E-06;0.000151733
11117;EMILIN1;down;elastin microfibril interfacer 1;1.402914643;4.453058215;1.88E-05;0.000740956
84436;ZNF528;down;zinc finger protein 528;1.404860053;3.976819871;5.28E-05;0.00132555
9953;HS3ST3B1;down;heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1;1.406085761;1.587777941;0.000432893;0.005514331
2842;GPR19;down;G protein-coupled receptor 19;1.40609055;1.859414044;0.001925984;0.014962861
116173;CMTM5;down;CKLF-like MARVEL transmembrane domain containing 5;1.40656469;5.705539692;3.43E-05;0.001061771
9355;LHX2;down;LIM homeobox 2;1.407411531;2.413344602;6.71E-05;0.001558825
29931;LINC00312;down;long intergenic non-protein coding RNA 312;1.408448127;-0.526868748;0.00928574;0.04526407
7490;WT1;down;Wilms tumor 1;1.408619392;2.854204115;0.000250957;0.003740552
161882;ZFPM1;down;zinc finger protein, FOG family member 1;1.41131105;4.840998622;2.26E-06;0.000218821
810;CALML3;down;calmodulin-like 3;1.418048602;0.121727554;0.008094104;0.041133412
9935;MAFB;down;v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B;1.421560362;2.131426386;0.001176355;0.010743996
115572;FAM46B;down;family with sequence similarity 46, member B;1.42236274;1.070977109;0.00252725;0.018148755
10678;B3GNT2;down;UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2;1.423811651;4.643841792;0.000171206;0.00288161
147804;TPM3P9;down;tropomyosin 3 pseudogene 9;1.424223512;4.080495073;3.91E-05;0.001122022
1278;COL1A2;down;collagen, type I, alpha 2;1.424770206;7.943874963;2.03E-07;7.07E-05
3624;INHBA;down;inhibin, beta A;1.4281256;1.009194103;0.001930499;0.01498183
8787;RGS9;down;regulator of G-protein signaling 9;1.430146412;0.989695144;0.000785579;0.008136032
101929215;CTD-2201I18.1;down;uncharacterized LOC101929215;1.430959226;1.088759757;0.00045721;0.005703491
9402;GRAP2;down;GRB2-related adaptor protein 2;1.430995632;1.02428973;0.001391967;0.012079866
6447;SCG5;down;secretogranin V;1.432664546;1.073841671;0.004598624;0.027795529
64411;ARAP3;down;ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3;1.440404129;1.68114863;0.000428765;0.005490774
51313;FAM198B;down;family with sequence similarity 198, member B;1.440539937;4.882375717;0.000708839;0.007630967
2;A2M;down;alpha-2-macroglobulin;1.440639247;5.920656929;5.49E-06;0.000369398
9108;MTMR7;down;myotubularin related protein 7;1.449164788;2.467349502;0.000115151;0.002228714
9915;ARNT2;down;aryl-hydrocarbon receptor nuclear translocator 2;1.458244501;3.183636828;2.94E-05;0.000954343
285175;UNC80;down;unc-80 homolog (C. elegans);1.458775341;4.446121349;3.74E-06;0.000292584
1299;COL9A3;down;collagen, type IX, alpha 3;1.461254061;2.233811287;0.000535138;0.006344528
9865;TRIL;down;TLR4 interactor with leucine-rich repeats;1.461691674;1.659472975;0.009938461;0.04761109
23657;SLC7A11;down;solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11;1.465988833;3.491332309;0.000155711;0.002725507
59;ACTA2;down;actin, alpha 2, smooth muscle, aorta;1.472313534;6.07189483;2.52E-06;0.000229711
392490;FLJ44635;down;TPT1-like protein;1.476466055;0.014690309;0.005239625;0.030521553
151126;ZNF385B;down;zinc finger protein 385B;1.4783615;3.251291165;4.02E-05;0.001133678
1129;CHRM2;down;cholinergic receptor, muscarinic 2;1.482056663;5.069330034;3.61E-05;0.001082717
5271;SERPINB8;down;serpin peptidase inhibitor, clade B (ovalbumin), member 8;1.482811915;0.28192665;0.006289361;0.034691524
27065;NSG1;down;neuron specific gene family member 1;1.485516103;4.115734005;1.55E-05;0.000676028
51421;AMOTL2;down;angiomotin like 2;1.485711563;6.634671434;0.002723076;0.019265291
2317;FLNB;down;filamin B, beta;1.485832629;7.319361157;4.04E-05;0.001135425
3084;NRG1;down;neuregulin 1;1.485833105;1.90331272;0.000146401;0.00263086
11249;NXPH2;down;neurexophilin 2;1.489853732;2.428390086;0.00076254;0.008000584
54997;TESC;down;tescalcin;1.491451199;4.848328339;4.47E-06;0.000326242
90187;EMILIN3;down;elastin microfibril interfacer 3;1.49776561;-0.19240525;0.003244552;0.021879543
115361;GBP4;down;guanylate binding protein 4;1.500766108;2.227260201;0.000223769;0.003435204
22843;PPM1E;down;protein phosphatase, Mg2+/Mn2+ dependent, 1E;1.501234519;0.211575684;0.00157063;0.013078917
3486;IGFBP3;down;insulin-like growth factor binding protein 3;1.502923785;3.305651076;0.00637481;0.03500456
79698;ZMAT4;down;zinc finger, matrin-type 4;1.502984984;4.651779603;5.51E-05;0.00136509
10267;RAMP1;down;receptor (G protein-coupled) activity modifying protein 1;1.505195926;0.717727569;0.005009544;0.029490224
79158;GNPTAB;down;N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits;1.506562278;5.28683353;1.33E-06;0.00015367
347730;LRRTM1;down;leucine rich repeat transmembrane neuronal 1;1.510600414;6.060444954;5.44E-06;0.000369398
3164;NR4A1;down;nuclear receptor subfamily 4, group A, member 1;1.511885324;5.410107594;0.002830081;0.019850539
143903;LAYN;down;layilin;1.514857941;0.790190861;0.001208008;0.010936371
NA;C12orf79;down;NA;1.518965665;1.660917494;0.000931546;0.009143444
10903;MTMR11;down;myotubularin related protein 11;1.526253168;2.614001107;4.37E-05;0.001188112
23576;DDAH1;down;dimethylarginine dimethylaminohydrolase 1;1.529649339;5.55437719;6.27E-06;0.000397812
81788;NUAK2;down;NUAK family, SNF1-like kinase, 2;1.52995591;2.39989734;0.000802523;0.008258272
59277;NTN4;down;netrin 4;1.531201354;2.103356376;0.000391727;0.005139379
5592;PRKG1;down;protein kinase, cGMP-dependent, type I;1.538430208;2.989679644;1.89E-05;0.000740956
10625;IVNS1ABP;down;influenza virus NS1A binding protein;1.544323656;8.268965751;5.51E-05;0.00136509
151887;CCDC80;down;coiled-coil domain containing 80;1.544545484;6.062645342;1.80E-05;0.000727866
9723;SEMA3E;down;sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E;1.545378019;1.584396934;0.006258316;0.034588198
1009;CDH11;down;cadherin 11, type 2, OB-cadherin (osteoblast);1.557529397;6.033930215;2.48E-07;7.61E-05
8321;FZD1;down;frizzled class receptor 1;1.560960151;5.360334569;3.99E-07;8.61E-05
2199;FBLN2;down;fibulin 2;1.564689606;6.887448353;6.35E-07;0.000104326
43;ACHE;down;acetylcholinesterase (Yt blood group);1.566366268;4.527040219;1.84E-06;0.00018595
5208;PFKFB2;down;6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2;1.568121982;4.822433971;3.94E-06;0.000300497
22871;NLGN1;down;neuroligin 1;1.570129604;2.948650105;1.75E-05;0.000721255
24141;LAMP5;down;lysosomal-associated membrane protein family, member 5;1.573409998;3.041800713;4.07E-05;0.001139271
5328;PLAU;down;plasminogen activator, urokinase;1.573529739;1.293083911;0.000480277;0.005908799
4133;MAP2;down;microtubule-associated protein 2;1.573700224;1.297571337;0.000649918;0.007211446
84239;ATP13A4;down;ATPase type 13A4;1.574952799;1.337043758;0.001583546;0.013135347
10129;FRY;down;furry homolog (Drosophila);1.57873218;5.020637342;2.31E-06;0.000222879
399947;C11orf87;down;chromosome 11 open reading frame 87;1.578804434;1.213758033;0.000428061;0.005490774
9638;FEZ1;down;fasciculation and elongation protein zeta 1 (zygin I);1.581978555;5.997901045;1.75E-06;0.000180405
27254;CSDC2;down;cold shock domain containing C2, RNA binding;1.582829503;2.313880343;6.44E-05;0.001512809
375616;KCP;down;kielin/chordin-like protein;1.586120091;1.252542246;0.000482145;0.005917532
649264;CES5AP1;down;carboxylesterase 5A pseudogene 1;1.587402455;0.615325355;0.002759915;0.019445835
375611;SLC26A5;down;solute carrier family 26 (anion exchanger), member 5;1.589302975;0.298213864;0.002016113;0.015341559
4313;MMP2;down;matrix metallopeptidase 2;1.591008411;5.004589635;8.83E-07;0.000122554
2893;GRIA4;down;glutamate receptor, ionotropic, AMPA 4;1.594787133;1.747863675;0.005358958;0.031027865
2113;ETS1;down;v-ets avian erythroblastosis virus E26 oncogene homolog 1;1.604046965;3.246416329;0.000756338;0.007959051
64651;CSRNP1;down;cysteine-serine-rich nuclear protein 1;1.608323428;3.189703128;0.000165622;0.00283931
2252;FGF7;down;fibroblast growth factor 7;1.609461841;4.851278673;4.89E-06;0.000343415
7291;TWIST1;down;twist family bHLH transcription factor 1;1.613702829;2.349751708;7.05E-05;0.001606597
11135;CDC42EP1;down;CDC42 effector protein (Rho GTPase binding) 1;1.61408904;2.533612573;0.001263173;0.01131682
84709;MGARP;down;mitochondria-localized glutamic acid-rich protein;1.619006629;3.475294916;1.86E-05;0.000735059
55959;SULF2;down;sulfatase 2;1.620722591;4.325080356;4.35E-06;0.000319605
23057;NMNAT2;down;nicotinamide nucleotide adenylyltransferase 2;1.629286594;2.345408101;0.001164687;0.010684674
2596;GAP43;down;growth associated protein 43;1.633016133;1.909702418;0.000192056;0.003112949
8516;ITGA8;down;integrin, alpha 8;1.635956166;2.261677928;0.000635058;0.00710106
375033;PEAR1;down;platelet endothelial aggregation receptor 1;1.642258174;1.451194609;0.000824444;0.008388321
9227;LRAT;down;lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase);1.645030821;4.819898366;1.93E-06;0.000190903
23026;MYO16;down;myosin XVI;1.646911813;1.517562003;0.00070641;0.00761616
3481;IGF2;down;insulin-like growth factor 2;1.650976957;3.563316389;0.001061192;0.009986948
84109;QRFPR;down;pyroglutamylated RFamide peptide receptor;1.65288636;3.018220353;5.95E-05;0.001440658
147372;CCBE1;down;collagen and calcium binding EGF domains 1;1.656601993;1.083887822;0.004858766;0.028837456
57221;ARFGEF3;down;ARFGEF family member 3;1.656886414;3.866331378;3.14E-06;0.000266512
10085;EDIL3;down;EGF-like repeats and discoidin I-like domains 3;1.657089325;2.271647213;0.001099305;0.01021449
6446;SGK1;down;serum/glucocorticoid regulated kinase 1;1.659730107;1.680055056;0.000117362;0.002247452
3680;ITGA9;down;integrin, alpha 9;1.661507158;2.878665309;1.70E-05;0.000711148
683;BST1;down;bone marrow stromal cell antigen 1;1.664473841;0.272880237;0.006069498;0.033790068
55106;SLFN12;down;schlafen family member 12;1.664499218;0.176911204;0.001381391;0.012045931
152404;IGSF11;down;immunoglobulin superfamily, member 11;1.6713663;2.242651443;5.71E-05;0.001397422
441376;AARD;down;alanine and arginine rich domain containing protein;1.67197843;0.972170173;0.000954251;0.009278122
3106;HLA-B;down;major histocompatibility complex, class I, B;1.676478725;0.981541787;0.001797745;0.0142488
9901;SRGAP3;down;SLIT-ROBO Rho GTPase activating protein 3;1.681223572;5.161115553;9.51E-07;0.000128554
150244;ZDHHC8P1;down;zinc finger, DHHC-type containing 8 pseudogene 1;1.681423296;3.44677753;1.04E-05;0.000521425
2255;FGF10;down;fibroblast growth factor 10;1.682367084;3.449457446;2.98E-05;0.000963096
9056;SLC7A7;down;solute carrier family 7 (amino acid transporter light chain, y+L system), member 7;1.684405417;0.915519665;0.003653825;0.023678622
340533;KIAA2022;down;KIAA2022;1.695787763;1.763444852;5.02E-05;0.001295167
139081;MAGEC3;down;melanoma antigen family C3;1.695874726;-0.446493025;0.007863092;0.04029939
55359;STYK1;down;serine/threonine/tyrosine kinase 1;1.695936524;0.691465968;0.001180473;0.010768003
11075;STMN2;down;stathmin 2;1.696629319;0.974929355;0.00687798;0.036828016
1302;COL11A2;down;collagen, type XI, alpha 2;1.703152373;1.738988499;9.32E-05;0.001911779
23604;DAPK2;down;death-associated protein kinase 2;1.704179228;0.110483642;0.001913517;0.014906053
2000;ELF4;down;E74-like factor 4 (ets domain transcription factor);1.704279181;1.17041072;0.001514874;0.012778325
23768;FLRT2;down;fibronectin leucine rich transmembrane protein 2;1.71089378;5.000061184;6.12E-06;0.000394874
2674;GFRA1;down;GDNF family receptor alpha 1;1.712860736;1.329193036;0.003669629;0.023738478
152273;FGD5;down;FYVE, RhoGEF and PH domain containing 5;1.713950303;1.141051994;0.000224568;0.003442945
7114;TMSB4X;down;thymosin beta 4, X-linked;1.717259368;5.400990784;1.26E-06;0.000151733
65989;DLK2;down;delta-like 2 homolog (Drosophila);1.732878555;1.506272469;0.000133952;0.002457713
2827;GPR3;down;G protein-coupled receptor 3;1.733921549;0.857950096;0.005262753;0.030601802
9628;RGS6;down;regulator of G-protein signaling 6;1.739070881;3.532736722;6.49E-06;0.000404749
887;CCKBR;down;cholecystokinin B receptor;1.739939588;3.163812999;7.41E-06;0.000432213
744;MPPED2;down;metallophosphoesterase domain containing 2;1.740522212;6.380003055;8.89E-08;5.66E-05
7093;TLL2;down;tolloid-like 2;1.750887988;-0.620431362;0.002536391;0.01819908
2492;FSHR;down;follicle stimulating hormone receptor;1.754601516;2.09685456;0.000718496;0.00770053
50940;PDE11A;down;phosphodiesterase 11A;1.754691705;1.580972866;0.00148996;0.012616978
79605;PGBD5;down;piggyBac transposable element derived 5;1.759561623;0.934278725;0.000217739;0.003384038
114800;CCDC85A;down;coiled-coil domain containing 85A;1.765061505;3.953860168;8.12E-06;0.000460058
869;CBLN1;down;cerebellin 1 precursor;1.77356125;1.363001928;0.001457577;0.012440167
9717;SEC14L5;down;SEC14-like lipid binding 5;1.775060984;1.653343141;0.001480471;0.012589487
2925;GRPR;down;gastrin-releasing peptide receptor;1.775205719;1.182400188;0.000612526;0.006897121
390;RND3;down;Rho family GTPase 3;1.778586612;2.216686668;0.001274019;0.011370226
1825;DSC3;down;desmocollin 3;1.793159021;0.891298817;0.001137261;0.010472945
170689;ADAMTS15;down;ADAM metallopeptidase with thrombospondin type 1 motif, 15;1.794239135;6.360111743;3.57E-06;0.000285299
2622;GAS8;down;growth arrest-specific 8;1.794892241;3.454665018;1.41E-05;0.000635202
201780;SLC10A4;down;solute carrier family 10, member 4;1.794901917;0.280859026;0.002252663;0.016591442
1368;CPM;down;carboxypeptidase M;1.795343677;3.258615892;0.000669931;0.007360077
8871;SYNJ2;down;synaptojanin 2;1.798230785;3.476019916;1.69E-05;0.000708203
7010;TEK;down;TEK tyrosine kinase, endothelial;1.800476322;0.659560844;0.001090726;0.010160902
11227;GALNT5;down;polypeptide N-acetylgalactosaminyltransferase 5;1.802745877;2.967299253;9.72E-06;0.000502062
5143;PDE4C;down;phosphodiesterase 4C, cAMP-specific;1.80583674;5.207243071;0.000770437;0.008025201
92558;CCDC64;down;coiled-coil domain containing 64;1.807386714;0.502243479;0.001806496;0.014280113
956;ENTPD3;down;ectonucleoside triphosphate diphosphohydrolase 3;1.807684254;-0.253975833;0.001847664;0.014541928
27075;TSPAN13;down;tetraspanin 13;1.809736816;6.952816466;1.33E-06;0.00015367
51207;DUSP13;down;dual specificity phosphatase 13;1.811791176;0.062126542;0.001084321;0.010114266
642366;LOC642366;down;uncharacterized LOC642366;1.813359031;4.94049931;2.71E-07;8.17E-05
9424;KCNK6;down;potassium channel, two pore domain subfamily K, member 6;1.813557089;1.699994339;0.000424108;0.005455297
220164;DOK6;down;docking protein 6;1.81438129;4.863884732;7.43E-07;0.000109573
55107;ANO1;down;anoctamin 1, calcium activated chloride channel;1.814494785;-0.177072766;0.001658176;0.013567575
2561;GABRB2;down;gamma-aminobutyric acid (GABA) A receptor, beta 2;1.817288413;1.830361524;0.000326992;0.004524062
8715;NOL4;down;nucleolar protein 4;1.824671623;-0.574169325;0.001903196;0.014841644
344148;NCKAP5;down;NCK-associated protein 5;1.824982824;-0.034339651;0.001069154;0.010021933
4753;NELL2;down;neural EGFL like 2;1.826047112;4.955336698;3.30E-07;8.61E-05
441282;AKR1B15;down;aldo-keto reductase family 1, member B15;1.830036206;1.412610125;0.000373176;0.00500064
1295;COL8A1;down;collagen, type VIII, alpha 1;1.834291291;2.157140229;0.00076037;0.007983604
404281;YY2;down;YY2 transcription factor;1.83657614;1.00712466;0.000243902;0.003669442
66004;LYNX1;down;Ly6/neurotoxin 1;1.839009644;2.740833409;1.36E-05;0.000617599
4609;MYC;down;v-myc avian myelocytomatosis viral oncogene homolog;1.839694332;2.596212601;0.000260511;0.003828772
5366;PMAIP1;down;phorbol-12-myristate-13-acetate-induced protein 1;1.84365854;-0.002454231;0.00094721;0.009246967
5354;PLP1;down;proteolipid protein 1;1.846740066;0.224599962;0.000624843;0.007008521
90768;LOC90768;down;uncharacterized LOC90768;1.84784747;3.758415486;1.33E-06;0.00015367
166863;RBM46;down;RNA binding motif protein 46;1.850877307;1.337953371;0.000262901;0.003851083
160428;ALDH1L2;down;aldehyde dehydrogenase 1 family, member L2;1.854221455;1.763355533;0.001571587;0.013078917
845;CASQ2;down;calsequestrin 2 (cardiac muscle);1.85736275;1.833889888;7.60E-05;0.001679769
58480;RHOU;down;ras homolog family member U;1.861445917;2.083436091;2.40E-05;0.000858273
344838;PAQR9;down;progestin and adipoQ receptor family member IX;1.862361155;0.612414186;0.000533849;0.006341301
51678;MPP6;down;membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6);1.866441134;5.867719161;3.25E-07;8.61E-05
55244;SLC47A1;down;solute carrier family 47 (multidrug and toxin extrusion), member 1;1.86657342;7.025438407;2.38E-07;7.48E-05
8292;COLQ;down;collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase;1.86676201;6.174676409;0.0001027;0.002054775
3491;CYR61;down;cysteine-rich, angiogenic inducer, 61;1.873369554;6.700120114;0.003591757;0.023428612
5069;PAPPA;down;pregnancy-associated plasma protein A, pappalysin 1;1.875230491;2.869551474;1.62E-05;0.000699702
100506621;LINC01279;down;long intergenic non-protein coding RNA 1279;1.876684905;2.527806863;0.00117154;0.01072712
23764;MAFF;down;v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F;1.880901907;1.638367059;0.000582815;0.006703709
9496;TBX4;down;T-box 4;1.881317175;0.251146045;0.000712217;0.007661636
79953;SYNDIG1;down;synapse differentiation inducing 1;1.881599225;1.381849914;0.000111305;0.002177609
79776;ZFHX4;down;zinc finger homeobox 4;1.882300887;2.156103765;2.43E-05;0.000866048
4638;MYLK;down;myosin light chain kinase;1.88533148;1.081431788;0.000191171;0.003109052
2861;GPR37;down;G protein-coupled receptor 37 (endothelin receptor type B-like);1.898055765;6.694505373;2.28E-07;7.31E-05
11346;SYNPO;down;synaptopodin;1.902614251;4.32653538;3.93E-07;8.61E-05
1850;DUSP8;down;dual specificity phosphatase 8;1.915357032;2.575837372;0.000321604;0.004470918
5159;PDGFRB;down;platelet-derived growth factor receptor, beta polypeptide;1.922499804;2.433633397;0.000782252;0.008113007
6616;SNAP25;down;synaptosomal-associated protein, 25kDa;1.923679431;3.715666927;3.28E-06;0.000269743
152330;CNTN4;down;contactin 4;1.927844326;3.443968403;2.20E-05;0.000806402
2034;EPAS1;down;endothelial PAS domain protein 1;1.93039106;2.315205127;1.24E-05;0.000585781
441027;TMEM150C;down;transmembrane protein 150C;1.930485059;2.963627278;2.86E-05;0.000935585
340527;NHSL2;down;NHS-like 2;1.930855983;3.049039274;1.11E-05;0.000538779
1848;DUSP6;down;dual specificity phosphatase 6;1.932090857;6.63468797;9.31E-05;0.001911192
8407;TAGLN2;down;transgelin 2;1.933333029;3.331271042;3.04E-06;0.000262982
161357;MDGA2;down;MAM domain containing glycosylphosphatidylinositol anchor 2;1.936091051;2.334286559;1.66E-05;0.00070361
5251;PHEX;down;phosphate regulating endopeptidase homolog, X-linked;1.940388688;0.16610115;0.006401369;0.035069763
149773;APCDD1L-AS1;down;APCDD1L antisense RNA 1 (head to head);1.940399136;-0.257201621;0.000979627;0.009436011
2650;GCNT1;down;glucosaminyl (N-acetyl) transferase 1, core 2;1.9472764;1.168761919;0.000123196;0.002343642
50944;SHANK1;down;SH3 and multiple ankyrin repeat domains 1;1.955510955;2.296450029;0.000150795;0.002688272
1002;CDH4;down;cadherin 4, type 1, R-cadherin (retinal);1.958057052;4.985580438;8.10E-07;0.000116506
53942;CNTN5;down;contactin 5;1.958639334;2.82831705;0.001061692;0.009986948
27063;ANKRD1;down;ankyrin repeat domain 1 (cardiac muscle);1.96042508;8.353709756;0.000422812;0.005443465
25817;FAM19A5;down;family with sequence similarity 19 (chemokine (C-C motif)-like), member A5;1.966463959;0.191431808;0.001184244;0.010795588
1404;HAPLN1;down;hyaluronan and proteoglycan link protein 1;1.967762436;5.118865057;1.17E-05;0.000563896
1959;EGR2;down;early growth response 2;1.968716582;0.886085714;6.02E-05;0.001451139
644150;WIPF3;down;WAS/WASL interacting protein family, member 3;1.969702388;6.199446889;3.22E-06;0.000269467
1496;CTNNA2;down;catenin (cadherin-associated protein), alpha 2;1.97345851;3.258208741;3.91E-05;0.001122022
6855;SYP;down;synaptophysin;1.97766932;-0.42685361;0.001539895;0.012903516
51232;CRIM1;down;cysteine rich transmembrane BMP regulator 1 (chordin-like);1.983166543;4.916730657;5.49E-06;0.000369398
7852;CXCR4;down;chemokine (C-X-C motif) receptor 4;1.983999857;2.085550834;2.13E-05;0.000792577
10381;TUBB3;down;tubulin, beta 3 class III;1.984439617;1.460509391;0.000185734;0.003044611
137735;ABRA;down;actin binding Rho activating protein;1.98462021;6.179220689;0.00106957;0.010021933
2059;EPS8;down;epidermal growth factor receptor pathway substrate 8;1.988767255;3.213972245;0.000101996;0.002053836
1839;HBEGF;down;heparin-binding EGF-like growth factor;1.989874868;3.116701137;7.11E-06;0.00042117
7345;UCHL1;down;ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase);1.991567964;4.158205717;4.95E-07;8.84E-05
121601;ANO4;down;anoctamin 4;1.995987742;0.056392704;0.00064356;0.007162882
6332;SCN7A;down;sodium channel, voltage gated, type VII alpha subunit;2.002334863;2.36132072;0.000146482;0.00263086
63895;PIEZO2;down;piezo-type mechanosensitive ion channel component 2;2.003770971;0.197480074;0.001485091;0.012597502
9957;HS3ST1;down;heparan sulfate (glucosamine) 3-O-sulfotransferase 1;2.011511075;-0.077781143;0.000693505;0.007516269
23242;COBL;down;cordon-bleu WH2 repeat protein;2.013587164;3.890669377;1.89E-06;0.00018882
5274;SERPINI1;down;serpin peptidase inhibitor, clade I (neuroserpin), member 1;2.024248549;4.691454578;7.29E-07;0.000109573
5015;OTX2;down;orthodenticle homeobox 2;2.026774956;3.649874634;1.86E-06;0.000186441
100132159;CALML3-AS1;down;CALML3 antisense RNA 1;2.033676246;2.15003226;0.000217853;0.003384038
4914;NTRK1;down;neurotrophic tyrosine kinase, receptor, type 1;2.040549422;3.140635738;9.95E-06;0.000511339
460;ASTN1;down;astrotactin 1;2.043072824;4.736459566;2.77E-06;0.000245822
9388;LIPG;down;lipase, endothelial;2.044278653;0.325452085;0.000160459;0.002778125
397;ARHGDIB;down;Rho GDP dissociation inhibitor (GDI) beta;2.050207892;0.014119293;0.001468821;0.012513978
55576;STAB2;down;stabilin 2;2.063507141;0.654547309;0.000127683;0.002391237
266743;NPAS4;down;neuronal PAS domain protein 4;2.067761992;2.525398605;1.30E-05;0.000600287
7026;NR2F2;down;nuclear receptor subfamily 2, group F, member 2;2.071284624;3.161602011;2.22E-06;0.00021692
7070;THY1;down;Thy-1 cell surface antigen;2.071644222;0.594782153;0.000152354;0.002702735
2202;EFEMP1;down;EGF containing fibulin-like extracellular matrix protein 1;2.072889121;0.716455219;0.000273703;0.003973095
57528;KCTD16;down;potassium channel tetramerization domain containing 16;2.076184531;1.042474042;6.74E-05;0.001558825
8507;ENC1;down;ectodermal-neural cortex 1 (with BTB domain);2.076204899;3.803983713;1.45E-05;0.000647557
23336;SYNM;down;synemin, intermediate filament protein;2.077327405;4.765583335;3.13E-06;0.000266512
3554;IL1R1;down;interleukin 1 receptor, type I;2.081640721;0.013203524;0.000636904;0.007115527
84981;MIR22HG;down;MIR22 host gene;2.086971177;4.744170885;8.73E-06;0.000476782
79870;BAALC;down;brain and acute leukemia, cytoplasmic;2.089671065;2.47111628;3.56E-05;0.001075197
55531;ELMOD1;down;ELMO/CED-12 domain containing 1;2.099813644;-0.39844581;0.001403204;0.012140949
59272;ACE2;down;angiotensin I converting enzyme 2;2.102306643;2.242646221;2.88E-05;0.000939115
10279;PRSS16;down;protease, serine, 16 (thymus);2.124061462;3.133354578;3.45E-05;0.001061771
158471;PRUNE2;down;prune homolog 2 (Drosophila);2.12846813;3.089047922;6.71E-06;0.000409214
8605;PLA2G4C;down;phospholipase A2, group IVC (cytosolic, calcium-independent);2.137732012;0.883887476;0.000103037;0.002054775
1946;EFNA5;down;ephrin-A5;2.13911404;1.910924254;2.60E-05;0.000883717
340024;SLC6A19;down;solute carrier family 6 (neutral amino acid transporter), member 19;2.143432032;2.252184994;8.74E-06;0.000476782
117154;DACH2;down;dachshund family transcription factor 2;2.147714729;0.665370865;0.000228497;0.003473824
9771;RAPGEF5;down;Rap guanine nucleotide exchange factor (GEF) 5;2.1482356;-0.272224422;0.00364783;0.023650371
249;ALPL;down;alkaline phosphatase, liver/bone/kidney;2.153007044;0.080713308;0.000485479;0.005952255
467;ATF3;down;activating transcription factor 3;2.154687673;3.645771977;2.53E-05;0.000877335
22822;PHLDA1;down;pleckstrin homology-like domain, family A, member 1;2.155790473;6.355172511;3.73E-07;8.61E-05
388630;TRABD2B;down;TraB domain containing 2B;2.156662131;5.448812352;1.01E-07;5.66E-05
85407;NKD1;down;naked cuticle homolog 1 (Drosophila);2.158235827;3.710204323;3.93E-07;8.61E-05
166614;DCLK2;down;doublecortin-like kinase 2;2.159030534;2.87184076;9.11E-06;0.000486276
2643;GCH1;down;GTP cyclohydrolase 1;2.159475087;2.386600469;5.19E-06;0.000355796
1906;EDN1;down;endothelin 1;2.162759122;2.199770408;0.000678059;0.007432426
83604;TMEM47;down;transmembrane protein 47;2.163172764;7.915955826;2.90E-07;8.23E-05
4254;KITLG;down;KIT ligand;2.17304791;2.528140987;2.43E-05;0.000866048
2335;FN1;down;fibronectin 1;2.180471751;10.96091758;3.97E-06;0.000300497
54857;GDPD2;down;glycerophosphodiester phosphodiesterase domain containing 2;2.184083042;1.246457078;3.56E-05;0.001075197
140730;RIMS4;down;regulating synaptic membrane exocytosis 4;2.202805729;1.849228461;2.25E-05;0.000815808
284656;EPHA10;down;EPH receptor A10;2.208792263;1.27186582;0.000177867;0.002955858
794;CALB2;down;calbindin 2;2.2158397;1.903660677;8.45E-05;0.001782812
6876;TAGLN;down;transgelin;2.216500065;6.855637081;6.19E-06;0.000396642
7039;TGFA;down;transforming growth factor, alpha;2.22111965;1.911221136;4.81E-05;0.001257012
145946;SPATA8;down;spermatogenesis associated 8;2.229793673;-0.208476805;0.00180964;0.014297145
639;PRDM1;down;PR domain containing 1, with ZNF domain;2.239300185;1.983612305;1.10E-05;0.000538779
2122;MECOM;down;MDS1 and EVI1 complex locus;2.240451784;3.738551518;2.49E-06;0.000229711
5414;sep-04;down;septin 4;2.240469473;2.859458857;7.36E-06;0.000432213
1620;BRINP1;down;bone morphogenetic protein/retinoic acid inducible neural-specific 1;2.243549843;1.584418422;2.09E-05;0.000788248
8482;SEMA7A;down;semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group);2.244486531;4.283276751;9.11E-06;0.000486276
11238;CA5B;down;carbonic anhydrase VB, mitochondrial;2.25290019;5.052471778;3.76E-06;0.000292584
221687;RNF182;down;ring finger protein 182;2.253394947;-0.134253193;0.009210562;0.045049493
51761;ATP8A2;down;ATPase, aminophospholipid transporter, class I, type 8A, member 2;2.263192467;2.309116573;9.62E-06;0.000500368
3645;INSRR;down;insulin receptor-related receptor;2.274281257;1.36412343;2.16E-05;0.000803109
146;ADRA1D;down;adrenoceptor alpha 1D;2.274634034;-0.236545444;0.001125751;0.010393431
6581;SLC22A3;down;solute carrier family 22 (organic cation transporter), member 3;2.289854438;0.527599359;0.000134582;0.002463028
2200;FBN1;down;fibrillin 1;2.291554528;3.70914547;2.42E-06;0.000228445
6376;CX3CL1;down;chemokine (C-X3-C motif) ligand 1;2.299843836;0.389724064;0.000628535;0.007044465
80852;GRIP2;down;glutamate receptor interacting protein 2;2.305026656;3.937913251;5.23E-05;0.001319758
10170;DHRS9;down;dehydrogenase/reductase (SDR family) member 9;2.308233656;0.680916041;0.000102773;0.002054775
5101;PCDH9;down;protocadherin 9;2.315749426;1.50982539;1.47E-05;0.000651723
5080;PAX6;down;paired box 6;2.320763772;2.094742918;1.01E-05;0.000514623
8412;BCAR3;down;breast cancer anti-estrogen resistance 3;2.322949348;3.585854231;3.28E-06;0.000269743
9586;CREB5;down;cAMP responsive element binding protein 5;2.324012735;2.908542318;0.000116383;0.002243403
2296;FOXC1;down;forkhead box C1;2.325088861;2.911803498;2.67E-06;0.000239538
6591;SNAI2;down;snail family zinc finger 2;2.327816192;2.624510781;3.50E-06;0.000281052
79924;ADM2;down;adrenomedullin 2;2.330757931;0.574853768;0.000429706;0.005493302
1490;CTGF;down;connective tissue growth factor;2.333755507;6.83418041;0.000486959;0.005956392
83481;EPPK1;down;epiplakin 1;2.340446037;2.750172903;1.05E-05;0.000523636
10586;MAB21L2;down;mab-21-like 2 (C. elegans);2.344077938;0.882916446;4.03E-05;0.001133992
203447;NRK;down;Nik related kinase;2.345066842;0.750184269;0.000257547;0.003807375
4745;NELL1;down;neural EGFL like 1;2.352075006;3.892309588;5.03E-06;0.000348083
25797;QPCT;down;glutaminyl-peptide cyclotransferase;2.353459735;-0.266478168;0.001079937;0.010092908
57616;TSHZ3;down;teashirt zinc finger homeobox 3;2.356508582;0.14588516;0.000191723;0.00311104
64084;CLSTN2;down;calsyntenin 2;2.357964873;5.919064489;2.37E-08;4.62E-05
2355;FOSL2;down;FOS-like antigen 2;2.363193514;2.587996793;5.64E-05;0.001381996
1281;COL3A1;down;collagen, type III, alpha 1;2.368053919;8.807989282;8.97E-06;0.000485637
8038;ADAM12;down;ADAM metallopeptidase domain 12;2.369159139;0.802946505;5.06E-05;0.001298406
2676;GFRA3;down;GDNF family receptor alpha 3;2.371033396;-0.134133982;0.000279434;0.004044106
216;ALDH1A1;down;aldehyde dehydrogenase 1 family, member A1;2.384296122;0.261586484;0.006954441;0.037061298
26507;CNNM1;down;cyclin and CBS domain divalent metal cation transport mediator 1;2.384569125;3.984897041;3.07E-06;0.000264017
57761;TRIB3;down;tribbles pseudokinase 3;2.407325353;1.788580914;0.000162948;0.002797977
79094;CHAC1;down;ChaC glutathione-specific gamma-glutamylcyclotransferase 1;2.411937249;1.564485875;0.000108714;0.002142028
26508;HEYL;down;hes-related family bHLH transcription factor with YRPW motif-like;2.430345962;1.373176308;1.27E-05;0.00059562
654463;FER1L6;down;fer-1-like family member 6;2.431053067;0.75386276;9.64E-05;0.001962415
54437;SEMA5B;down;sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B;2.432386157;0.613745646;0.000241184;0.003643714
9856;KIAA0319;down;KIAA0319;2.44396726;5.896909528;1.92E-07;7.07E-05
1293;COL6A3;down;collagen, type VI, alpha 3;2.449950736;5.306885788;0.000313528;0.004395304
81848;SPRY4;down;sprouty RTK signaling antagonist 4;2.461359864;6.031324033;3.75E-06;0.000292584
7980;TFPI2;down;tissue factor pathway inhibitor 2;2.461751641;3.793173727;6.50E-07;0.00010444
2662;GDF10;down;growth differentiation factor 10;2.464511806;2.565471081;3.42E-06;0.000276299
387758;FIBIN;down;fin bud initiation factor homolog (zebrafish);2.471115876;1.095577304;8.81E-05;0.001836041
100507308;TARID;down;TCF21 antisense RNA inducing promoter demethylation;2.484986505;1.656803943;4.82E-05;0.001257012
5579;PRKCB;down;protein kinase C, beta;2.501866955;2.488390242;8.56E-06;0.000470784
9363;RAB33A;down;RAB33A, member RAS oncogene family;2.506201544;0.176001808;0.000155507;0.002725237
84159;ARID5B;down;AT rich interactive domain 5B (MRF1-like);2.547753404;3.990998023;1.54E-06;0.000168219
84620;ST6GAL2;down;ST6 beta-galactosamide alpha-2,6-sialyltranferase 2;2.550563326;0.145549528;0.000223818;0.003435204
2313;FLI1;down;Fli-1 proto-oncogene, ETS transcription factor;2.553315022;-0.396204205;0.000253677;0.003765565
116496;FAM129A;down;family with sequence similarity 129, member A;2.556679116;1.632714839;8.25E-06;0.000460546
7088;TLE1;down;transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila);2.577611999;2.783980064;1.16E-06;0.000146618
9229;DLGAP1;down;discs, large (Drosophila) homolog-associated protein 1;2.577830362;3.332006725;3.56E-07;8.61E-05
400618;SOX9-AS1;down;SOX9 antisense RNA 1;2.5943794;0.805189857;5.32E-05;0.001332356
3670;ISL1;down;ISL LIM homeobox 1;2.595096621;5.318090973;2.45E-08;4.62E-05
131873;COL6A6;down;collagen, type VI, alpha 6;2.608561563;3.638346148;1.18E-06;0.000148238
9096;TBX18;down;T-box 18;2.610720001;5.164090987;4.81E-07;8.84E-05
3736;KCNA1;down;potassium channel, voltage gated shaker related subfamily A, member 1;2.61500291;0.570156323;0.000100491;0.002032026
827;CAPN6;down;calpain 6;2.616142371;0.962698492;1.66E-05;0.00070361
10451;VAV3;down;vav 3 guanine nucleotide exchange factor;2.618256679;0.623348645;4.38E-05;0.001188112
1268;CNR1;down;cannabinoid receptor 1 (brain);2.652432494;0.073849931;0.000156987;0.002741594
340543;TCEAL5;down;transcription elongation factor A (SII)-like 5;2.654741334;0.471204827;0.000136466;0.002484924
79966;SCD5;down;stearoyl-CoA desaturase 5;2.656869856;1.273895901;1.89E-05;0.000740956
320;APBA1;down;amyloid beta (A4) precursor protein-binding, family A, member 1;2.668359549;4.035957831;4.83E-07;8.84E-05
22989;MYH15;down;myosin, heavy chain 15;2.669131717;0.357348641;0.000153205;0.002712669
3778;KCNMA1;down;potassium channel, calcium activated large conductance subfamily M alpha, member 1;2.682632995;0.52123384;0.00016132;0.002783259
7057;THBS1;down;thrombospondin 1;2.683477508;6.456300313;1.28E-06;0.000152723
301;ANXA1;down;annexin A1;2.685466064;1.477670656;0.000607878;0.006866166
10418;SPON1;down;spondin 1, extracellular matrix protein;2.703182879;5.015847207;1.30E-07;6.03E-05
1303;COL12A1;down;collagen, type XII, alpha 1;2.703317914;1.154403549;8.00E-05;0.001721989
9201;DCLK1;down;doublecortin-like kinase 1;2.720965173;1.444631287;3.20E-06;0.000269298
164284;APCDD1L;down;adenomatosis polyposis coli down-regulated 1-like;2.727432588;3.155943448;7.21E-07;0.000109573
2719;GPC3;down;glypican 3;2.72751756;7.913959094;1.27E-05;0.00059562
6886;TAL1;down;T-cell acute lymphocytic leukemia 1;2.738190026;0.011951257;0.000470192;0.005830218
83729;INHBE;down;inhibin, beta E;2.738208498;1.427262062;0.000157812;0.002752279
2701;GJA4;down;gap junction protein, alpha 4, 37kDa;2.755797052;-0.755615462;7.81E-05;0.001710966
5139;PDE3A;down;phosphodiesterase 3A, cGMP-inhibited;2.756818782;4.14915874;5.75E-07;9.78E-05
375567;VWC2;down;von Willebrand factor C domain containing 2;2.761731452;2.71554437;1.67E-06;0.000176472
223117;SEMA3D;down;sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D;2.804019082;2.445742193;1.55E-06;0.000168542
8324;FZD7;down;frizzled class receptor 7;2.807375313;6.377845763;6.00E-07;0.000100796
57451;TENM2;down;teneurin transmembrane protein 2;2.818293243;3.080564402;8.90E-07;0.000122554
58;ACTA1;down;actin, alpha 1, skeletal muscle;2.8320144;6.204485228;0.00032093;0.004470918
400120;SERTM1;down;serine-rich and transmembrane domain containing 1;2.83680809;1.57942391;8.09E-05;0.001732417
2890;GRIA1;down;glutamate receptor, ionotropic, AMPA 1;2.853516135;5.462516135;3.85E-08;4.62E-05
3785;KCNQ2;down;potassium channel, voltage gated KQT-like subfamily Q, member 2;2.857728712;0.348032548;3.28E-05;0.001034169
57863;CADM3;down;cell adhesion molecule 3;2.869556344;3.498857771;3.54E-07;8.61E-05
139411;PTCHD1;down;patched domain containing 1;2.879602187;1.071390402;1.67E-05;0.00070361
347731;LRRTM3;down;leucine rich repeat transmembrane neuronal 3;2.888978043;4.425284614;1.99E-07;7.07E-05
23213;SULF1;down;sulfatase 1;2.896672673;2.409550752;5.59E-06;0.000373247
10544;PROCR;down;protein C receptor, endothelial;2.899450737;2.870077352;4.16E-07;8.69E-05
1012;CDH13;down;cadherin 13;2.904227047;6.672352981;1.18E-07;6.03E-05
5549;PRELP;down;proline/arginine-rich end leucine-rich repeat protein;2.929427982;-0.628351006;0.000301555;0.004266025
84889;SLC7A3;down;solute carrier family 7 (cationic amino acid transporter, y+ system), member 3;2.949681985;2.096413463;1.49E-06;0.000165739
6662;SOX9;down;SRY (sex determining region Y)-box 9;2.953237808;3.264173679;6.62E-06;0.000407036
3800;KIF5C;down;kinesin family member 5C;2.962903664;3.437380718;9.92E-07;0.000132832
29951;PDZRN4;down;PDZ domain containing ring finger 4;2.966414144;1.0821405;7.72E-06;0.000444457
4915;NTRK2;down;neurotrophic tyrosine kinase, receptor, type 2;2.995494135;3.283330712;1.02E-06;0.000133709
2897;GRIK1;down;glutamate receptor, ionotropic, kainate 1;3.001936557;0.421571998;3.46E-05;0.001061771
7056;THBD;down;thrombomodulin;3.005362644;-0.529770369;4.27E-05;0.001172647
343263;MYBPHL;down;myosin binding protein H-like;3.029760824;1.749310254;2.48E-06;0.000229711
64283;ARHGEF28;down;Rho guanine nucleotide exchange factor (GEF) 28;3.038752984;0.914824594;6.21E-05;0.001484697
5593;PRKG2;down;protein kinase, cGMP-dependent, type II;3.079001537;3.68566386;3.16E-07;8.61E-05
27092;CACNG4;down;calcium channel, voltage-dependent, gamma subunit 4;3.086232211;0.078529403;0.001974243;0.01517076
10468;FST;down;follistatin;3.086524886;5.203569934;4.13E-08;4.62E-05
57512;GPR158;down;G protein-coupled receptor 158;3.087342838;2.149569077;2.34E-05;0.000844209
5327;PLAT;down;plasminogen activator, tissue;3.187604072;4.123309938;1.07E-05;0.000530704
652;BMP4;down;bone morphogenetic protein 4;3.198312058;3.420154565;1.63E-06;0.000175018
2532;ACKR1;down;atypical chemokine receptor 1 (Duffy blood group);3.213826875;0.859721713;1.80E-05;0.000727866
2669;GEM;down;GTP binding protein overexpressed in skeletal muscle;3.214100346;2.068253315;6.37E-06;0.000400547
4045;LSAMP;down;limbic system-associated membrane protein;3.217739195;5.742388926;4.52E-07;8.80E-05
119587;CPXM2;down;carboxypeptidase X (M14 family), member 2;3.226049803;-0.52431151;0.005306251;0.030773276
64094;SMOC2;down;SPARC related modular calcium binding 2;3.290031368;-0.227599876;1.78E-05;0.000727866
27295;PDLIM3;down;PDZ and LIM domain 3;3.293555492;4.998862333;4.06E-07;8.63E-05
7060;THBS4;down;thrombospondin 4;3.299329237;6.180429708;7.89E-08;5.66E-05
2118;ETV4;down;ets variant 4;3.335236509;1.16337155;6.09E-06;0.000394618
57795;BRINP2;down;bone morphogenetic protein/retinoic acid inducible neural-specific 2;3.337709901;2.183617966;8.96E-05;0.001855418
2331;FMOD;down;fibromodulin;3.342588848;1.980759308;2.48E-06;0.000229711
4852;NPY;down;neuropeptide Y;3.361707846;1.755419195;4.35E-06;0.000319605
5618;PRLR;down;prolactin receptor;3.364284932;-0.422072203;7.01E-05;0.001603627
1641;DCX;down;doublecortin;3.365378352;4.359303145;6.21E-08;5.28E-05
2571;GAD1;down;glutamate decarboxylase 1 (brain, 67kDa);3.366974519;2.566002132;5.09E-07;8.98E-05
5054;SERPINE1;down;serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1;3.368951083;1.686559544;0.000200797;0.003204333
8013;NR4A3;down;nuclear receptor subfamily 4, group A, member 3;3.381485277;1.842289239;2.57E-05;0.000882925
3672;ITGA1;down;integrin, alpha 1;3.42883817;3.886493499;6.20E-06;0.000396642
440193;CCDC88C;down;coiled-coil domain containing 88C;3.436771554;1.304013532;1.11E-06;0.000141826
100506274;LOC100506274;down;uncharacterized LOC100506274;3.448020461;2.828191733;1.06E-06;0.000137383
1846;DUSP4;down;dual specificity phosphatase 4;3.466032606;0.969401747;1.65E-06;0.000175672
6943;TCF21;down;transcription factor 21;3.491105416;2.322720098;4.21E-07;8.69E-05
5794;PTPRH;down;protein tyrosine phosphatase, receptor type, H;3.495563919;-0.261037088;4.98E-05;0.00128925
348938;NIPAL4;down;NIPA-like domain containing 4;3.539616459;1.514771177;3.78E-05;0.001110333
6588;SLN;down;sarcolipin;3.554446886;-0.30890078;2.51E-05;0.000877052
7025;NR2F1;down;nuclear receptor subfamily 2, group F, member 1;3.563113605;2.230143662;2.77E-07;8.18E-05
50863;NTM;down;neurotrimin;3.578345221;3.060889013;9.39E-07;0.000128107
392255;GDF6;down;growth differentiation factor 6;3.681844162;0.199417297;3.88E-06;0.00029967
83894;TTC29;down;tetratricopeptide repeat domain 29;3.728803953;0.917885184;4.52E-06;0.000326576
22941;SHANK2;down;SH3 and multiple ankyrin repeat domains 2;3.814545831;-0.257634299;4.39E-05;0.001188112
51334;PRR16;down;proline rich 16;3.913210946;0.032574143;3.20E-05;0.001011899
4005;LMO2;down;LIM domain only 2 (rhombotin-like 1);3.920671487;5.048151403;5.69E-07;9.78E-05
5999;RGS4;down;regulator of G-protein signaling 4;3.990983137;3.431764069;1.77E-07;7.07E-05
4978;OPCML;down;opioid binding protein/cell adhesion molecule-like;4.007289188;4.571347414;3.83E-08;4.62E-05
2185;PTK2B;down;protein tyrosine kinase 2 beta;4.008326205;6.400073286;1.06E-08;4.62E-05
53353;LRP1B;down;low density lipoprotein receptor-related protein 1B;4.02946773;1.944114639;1.23E-06;0.000151116
388939;C2orf71;down;chromosome 2 open reading frame 71;4.042633095;2.091199799;1.93E-07;7.07E-05
4629;MYH11;down;myosin, heavy chain 11, smooth muscle;4.062635447;7.764765168;4.47E-07;8.80E-05
22998;LIMCH1;down;LIM and calponin homology domains 1;4.088306312;4.840292152;3.50E-07;8.61E-05
8840;WISP1;down;WNT1 inducible signaling pathway protein 1;4.089487537;-0.272170604;0.0002115;0.003312502
9745;ZNF536;down;zinc finger protein 536;4.37776509;-0.970446189;1.85E-05;0.000735059
5019;OXCT1;down;3-oxoacid CoA transferase 1;4.385078259;1.240291848;3.09E-07;8.60E-05
11259;FILIP1L;down;filamin A interacting protein 1-like;4.577189432;1.320390758;6.60E-06;0.000407036
25878;MXRA5;down;matrix-remodelling associated 5;4.770451603;2.495131594;8.70E-08;5.66E-05
5457;POU4F1;down;POU class 4 homeobox 1;4.80499223;2.094326911;9.31E-08;5.66E-05
10046;MAMLD1;down;mastermind-like domain containing 1;4.827394243;1.614520561;3.34E-07;8.61E-05
10800;CYSLTR1;down;cysteinyl leukotriene receptor 1;5.221854702;-0.976441032;1.70E-06;0.000177259
100505738;MIR4458HG;down;MIR4458 host gene;6.312129265;-0.43199139;3.71E-07;8.61E-05
